

ACCEPTED MANUSCRIPT • OPEN ACCESS

Real-time intrafraction motion monitoring in external beam radiotherapy

To cite this article before publication: Jenny Bertholet *et al* 2019 *Phys. Med. Biol.* in press <https://doi.org/10.1088/1361-6560/ab2ba8>

Manuscript version: Accepted Manuscript

Accepted Manuscript is “the version of the article accepted for publication including all changes made as a result of the peer review process, and which may also include the addition to the article by IOP Publishing of a header, an article ID, a cover sheet and/or an ‘Accepted Manuscript’ watermark, but excluding any other editing, typesetting or other changes made by IOP Publishing and/or its licensors”

This Accepted Manuscript is © 2019 Institute of Physics and Engineering in Medicine.

As the Version of Record of this article is going to be / has been published on a gold open access basis under a CC BY 3.0 licence, this Accepted Manuscript is available for reuse under a CC BY 3.0 licence immediately.

Everyone is permitted to use all or part of the original content in this article, provided that they adhere to all the terms of the licence <https://creativecommons.org/licenses/by/3.0>

Although reasonable endeavours have been taken to obtain all necessary permissions from third parties to include their copyrighted content within this article, their full citation and copyright line may not be present in this Accepted Manuscript version. Before using any content from this article, please refer to the Version of Record on IOPscience once published for full citation and copyright details, as permissions may be required. All third party content is fully copyright protected and is not published on a gold open access basis under a CC BY licence, unless that is specifically stated in the figure caption in the Version of Record.

View the [article online](#) for updates and enhancements.

Real-time intrafraction motion monitoring in external beam radiotherapy

Jenny Bertholet¹, Antje Knopf², Björn Eiben³, Jamie McClelland³, Alexander Grimwood¹, Emma Harris¹, Martin Menten¹, Per Poulsen⁴, Doan Trang Nguyen^{5,6}, Paul Keall⁵, Uwe Oelfke¹

¹ Joint Department of Physics, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK

² Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, the Netherlands.

³ Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, University College London, United Kingdom

⁴ Department of Oncology, Aarhus University Hospital, Aarhus, Denmark

⁵ ACRF Image X Institute, University of Sydney, Sydney, Australia

⁶ School of Biomedical Engineering, University of Technology Sydney, Sydney, Australia

Abstract

Radiotherapy (RT) aims to deliver a spatially conformal dose of radiation to tumours while maximizing the dose sparing to healthy tissues. However, the internal patient anatomy is constantly moving due to respiratory, cardiac, gastrointestinal and urinary activity. The long term goal of the RT community to “see what we treat, as we treat” and to act on this information instantaneously has resulted in rapid technological innovation. Specialized treatment machines, such as robotic or gimbal-steered linear accelerators (linac) with in-room imaging suites, have been developed specifically for real-time treatment adaptation. Additional equipment, such as stereoscopic kilovoltage (kV) imaging, ultrasound transducers and electromagnetic transponders, has been developed for intrafraction motion monitoring on conventional linacs. Magnetic resonance imaging (MRI) has been integrated with cobalt treatment units and more recently with linacs. In addition to hardware innovation, software development has played a substantial role in the development of motion monitoring methods based on respiratory motion surrogates and planar kV or Megavoltage (MV) imaging that is available on standard equipped linacs.

In this paper, we review and compare the different intrafraction motion monitoring methods proposed in the literature and demonstrated in real-time on clinical data as well as their possible future developments. We then discuss general considerations on validation and quality assurance for clinical implementation.

Besides photon RT, particle therapy is increasingly used to treat moving targets. However, transferring motion monitoring technologies from linacs to particle beam lines presents substantial challenges. Lessons learned from the implementation of real-time intrafraction monitoring for photon RT will be used as a basis to discuss the implementation of these methods for particle RT.

1. Introduction

5 Radiation therapy (RT) is a cornerstone of cancer treatment owing to its ability to selectively irradiate
6 tumoural tissues while sparing healthy tissues (Jaffray 2012). However, accurate spatial dose delivery
7 is challenging due to changes in internal anatomy occurring on different time scales. Patient set-up as
8 well as day-to-day changes in anatomy such as weight loss or tumour progression or shrinkage,
9 known as interfraction motion, can be monitored using image-guided radiotherapy (IGRT) prior to
10 treatment delivery. However, intrafractional changes due to bladder filling, peristalsis or tumour drift
11 happen on a shorter time scale of minutes which may require intrafraction monitoring. Even faster
12 motion caused by respiration or cardiac activity occurs which affects treatment accuracy and real-time
13 monitoring of this motion requires a high temporal frequency. Respiration-induced target motion
14 (translation, rotation and deformation) of several centimetres has been observed in liver (Case *et al*
15 2009, Worm *et al* 2013, Park *et al* 2012, Xu *et al* 2014, Bertholet *et al* 2016), lung (Schmidt *et al*
16 2016, Huang *et al* 2015, Seppenwoolde *et al* 2002, Kyriakou and McKenzie 2012) and pancreas
17 (Jones *et al* 2015, Campbell *et al* 2017a, Ahn *et al* 2004). Cardiac activity can also have a substantial
18 effect on the position of lung tumours, mediastinal lymph nodes (Seppenwoolde *et al* 2002, Scherman
19 Rydhög *et al* 2017, Schmidt *et al* 2016, Chen *et al* 2014) or liver tumours (Kitamura *et al* 2003,
20 Bertholet *et al* 2016). Erratic motion of the prostate, including rotation, was also reported in several
21 studies (Huang *et al* 2015, Poulsen *et al* 2008b, Ng *et al* 2012, Tynan *et al* 2016, Hunt *et al* 2016, Chi
22 *et al* 2017, Aubry *et al* 2004, Ghilezan *et al* 2005, Kupelian *et al* 2007, Langen *et al* 2008).
23

24 Motion of the tumour and the surrounding organs during the delivery of a plan designed on a static
25 anatomy may result in tumour underdosage and over-exposure of healthy tissues. In order to mitigate
26 the detrimental effect of motion on dose delivery, margins are a widely used passive approach aiming
27 at ensuring target coverage despite intrafraction motion either by encompassing the entire path
28 covered by the target during pre-treatment imaging using an internal target volume (ITV), or by using
29 probabilistic margins in a mid-ventilation approach (van Herk 2004, Stroom and Heijmen 2002).
30 However, ITV and mid-ventilation approaches may result in large irradiated volumes leading to high
31 dose delivery to the organs at risk (OAR) (Kamerling *et al* 2016a, Ehrbar *et al* 2016, Wolthaus *et al*
32 2008) while target coverage is not guaranteed, especially in the presence of tumour drift. Active
33 motion mitigation techniques such as tracking or gating (Keall *et al* 2006) allow for margin reduction
34 while ensuring target coverage but this requires real-time motion monitoring to trigger the beam
35 on/off signal during gating or the tracking feedback loop.
36

37 Intra-fraction motion monitoring and mitigation are particularly needed for stereotactic body RT
38 (SBRT), where an ablative dose is delivered to the tumour in a few fractions and tight margins are
39 needed to spare the healthy tissues. Because of the high dose delivered per fraction, delivery times are
40 also increased with two main consequences. First, large drifts and changes in breathing patterns are
41 more likely to occur within a fraction. Second, set-up and drift-related errors may no longer be
42 considered random in margins recipes (van Herk 2004, Herschthal *et al* 2013, Stroom and Heijmen
43 2002) and are likely to have a greater impact on dosimetric errors. SBRT with motion mitigation has
44 shown promising clinical outcome for abdominal tumours in the recent years (Su *et al* 2017b, Henke
45 *et al* 2018) and the high disease control rate observed for SBRT of early stage lung cancer patients
46 (Onishi *et al* 2007) is motivating the introduction of dose escalation and SBRT for locally advanced
47 lung cancer patients where targeting accuracy and margin reduction are key due to the large irradiated
48 volumes (Bainbridge *et al* 2017).
49

50 The actually delivered dose, taking motion into account, may be estimated from time-resolved motion
51 monitoring data (Poulsen *et al* 2012b, Kamerling *et al* 2017, Ravkilde *et al* 2018) and would arguably
52 allow to establish more accurate dose-response models than the planned dose (Siochi *et al* 2015,
53 Meijers *et al* 2019).
54

55 The interest in the RT community to “see what we treat, as we treat” and adapt treatment instantly has
56 led to the development of numerous real-time motion monitoring and mitigation techniques. Fully
57

1
2
3 integrated systems such as robotic linear accelerators (linac) and gimbal steered linacs with imaging
4 suites were specifically designed to combine motion monitoring with mitigation by dynamic tumour
5 tracking and are now routinely used (Depuydt *et al* 2014, Hoogeman *et al* 2009). Magnetic resonance
6 (MR) imaging was also integrated with treatment machines with two commercial systems (Mutic and
7 Dempsey 2014, Raaymakers *et al* 2017) where gating is applied on the MRIdian (Tetar *et al* 2018,
8 Green *et al* 2018) and multi-leaf collimator (MLC) tracking has been proposed on the Unity (Glitzner
9 *et al* 2018). Add-on systems such as electromagnetic transponders, surface imaging and ultrasound
10 transducers may be interfaced with conventional linacs for automatic gating of the treatment beam
11 (Worm *et al* 2018, Grimwood *et al* 2018). In addition, conventional linacs alone may provide 3D
12 motion monitoring capability (Keall *et al* 2018b) and mitigation via MLC tracking (Keall *et al* 2014b,
13 Booth *et al* 2016, Keall *et al* 2018a) or couch tracking (Ehrbar *et al* 2017b) although the latter has not
14 been used clinically to date.
15

16
17 In particle therapy, inline motion and anatomical changes along the beam path may have large
18 dosimetric effects that cannot fully be accounted for by the use of margins (Engelsman *et al* 2013, De
19 Ruysscher *et al* 2015). Particle therapy centres have seen the integration of add-on monitoring
20 equipment and on-board imaging similar to that of conventional linac systems. However, efforts to
21 translate motion monitoring approaches from photon therapy to particle therapy are still challenged by
22 the accuracy requirements of particle therapy and the technical challenges of integrating hardware-
23 focused systems in a particle therapy treatment room.
24

25
26 In this review, we present the different real-time motion monitoring methods used clinically in photon
27 or particle therapy and their possible future developments in section 2. Motion mitigation, active or
28 passive, will not be discussed in depth in this review; instead we refer the reader to the AAPM Task
29 group 76 report (Keall *et al* 2006), the paper by (Dieterich *et al* 2008) and, for proton therapy, to the
30 consensus guidelines of the PTCOG thoracic and lymphoma subcommittee (Chang *et al* 2017). In
31 section 3, we discuss the validation of motion monitoring methods at the development or early
32 implementation stage (3.1) and general considerations on quality assurance (QA) in clinical practice.
33 In section 4, the translation of the experience from photon therapy to particle therapy will be
34 discussed. Finally, section 5 concludes this review with a discussion of the presented method and an
35 outlook on the expected evolution of motion monitoring in photon and particle therapy.
36

37 2. Real-time intrafraction motion monitoring methods

38
39 In this review, the term “monitoring” will be used for the measurement (or estimation) of the tumour
40 or OAR position as a function of time while the term “tracking” will be used only to refer to the
41 action of following the tumour with the treatment beam. The tumour or OAR being monitored may
42 not be directly visible but monitored using a surrogate (internal or external). In addition, the position
43 of visible tumours and OARs is generally reduced to the centre of mass of the structure. Therefore in
44 this review, the term “target” refers to the surrogate position or to the centre of mass position for the
45 tumour or OAR being monitored. “Real-time monitoring” refers to the measurement and processing
46 (or estimation) of target position using solely information that is available at the time of interrogation
47 (e.g. image acquisition) with a time delay no longer than 0.5 s for the monitoring of respiratory
48 motion. The time delay may be longer for slow motion such as that of the prostate. “Online
49 monitoring” refers to monitoring while the patient is on the treatment table. The International
50 Organisation of Standardisation (ISO) 5725-1 (ISO 1994) defines the accuracy of a measure as a
51 combination of the trueness (mean error) and precision (standard deviation, SD, of the error).
52 Accuracy is often defined as the mean error in motion monitoring reports. In this review, we use the
53 term accuracy as intended by ISO 5725-1 and use mean and SD to report trueness and precision.
54

55
56 The different motion monitoring methods discussed in this review are listed in table 1. The
57 corresponding sections are indicated in parenthesis in the first column.
58

Table 1. Overview of the technologies used for real-time motion monitoring.

Technology (section)	Internal/external	Dimensions	Additional ionising radiation	Tissue/ Tumour/ surrogate	Additional equipment to standard linac	Online solution (vendor) if applicable
Infrared (2.1.1)	External	1D	No	Patient surface	No	RPM (Varian) respiratory gating (Figure 1a)
		6 DoF		Fixation devices	Yes	IRLED (Brainlab)
Optical (2.1.2)	External	6 DoF surface	No	Patient surface	Yes	Align RT (Vision RT) (Figure 1b) / Catalyst (C-RAD)
Spirometry (2.1.3)	External	1D	No	Lung volume changes	Yes	ABC (Elekta) (Figure 1c)
Pressure belt (2.1.3)	External	1D	No	Abdomen perimiter	Yes	Anzai (Anzai Medical) (Figure 1d) Bellows
Thermistor (2.1.3)	External	1D	No	Airflow temperature	Yes	Thermistor (non commercial)
kV/MV (2.2.2)	Internal	3D triangulated	Yes	Markers (prostate)	No	MSKCC (non commercial)
kV/kV (2.2.2)	Internal	3D triangulated	Yes	Markers (multi-site), vertebrae, Cranium	Dedicated machine	CyberKnife® (Accuray) (Figure 2c top)
				Markers (multi-site)	Dedicated machine	Vero (Figure 2c bottom) (Brainlab and Mitsubishi, discontinued)
				Markers (multi-site)	Yes	RTRT (non commercial)
				Lung and liver tumours	Yes	Stereoscopic markerless monitoring (non commercial)
MV (2.2.3)	Internal	2D Beam's Eye View	No	Markers, lung tumour	No	No online solution
		3D inferred		Markers (prostate)		
kV (2.2.3)	Internal	3D inferred	Yes	Markers (multi-site), vertebrae, bronchi, lung tumours	No	KIM (non commercial, Online only for prostate) and sequential stereoscopic (non commercial, online only for vertebrae)
		6D inferred		Markers		KIM, not performed online
Hybrid (2.3)	Internal with correlation model	3D	Yes	Markers (multi-site), lung tumours	Dedicated machine	CyberKnife® Synchrony (Accuray) (Figure 2c top)
				Markers (multi-site)	Dedicated machine	Vero (Figure 2c bottom) (Brainlab and Mitsubishi, discontinued)
				Markers (multi-site), cranium	Yes	ExacTrac (Brainlab) (Figure 2b)
				Markers (lung)	Yes	RTRT + Anzai (non commercial)
				Markers (liver)	No	COSMIK (non commercial)
Electromagnetic (2.4.1)	Internal	3D	No	Markers (multi-site)	Yes	Calypso (Varian) and raypilot (MicroPos Medical, only prostate) (figure 5)
Ultrasound (2.4.2)	Internal	3D	No	Prostate, prostate bed	Yes	Clarity autoscan (Elekta) (Figure 5d)
				Soft tissues		Modified 4D ultrasound system (non commercial)
MR (2.5)	Internal	2D cine (any orientation)	No	Tissues	Dedicated machine	Unity (Elekta), MRIdian (ViewRay) (Figure 2d)

2.1. Surface imaging and respiratory monitoring

Respiratory monitoring can provide a surrogate for target motion in the thorax or abdomen and was proposed early on for gating (Kubo and Hill 1996). Audio-visual feedback to the patient may help improve breathing reproducibility. Surface imaging can provide direct target monitoring in the case of chest wall or breast irradiation. It is also considered to be a very reliable surrogate for intracranial targets. These methods are characterized by the ease of use and high temporal frequency without imposing additional imaging dose to the patient. However, for respiratory monitoring, they rely on the stability of the relationship between a certain respiratory level and the target position.

2.1.1. Infrared-based monitoring

Intracranial stereotactic radiosurgery (SRS) requires highly accurate treatment delivery. Infrared (IR)-based monitoring is a non-invasive alternative to fixed-pin systems where a coordinate frame is mechanically fixed to the patient's skull (Lightstone *et al* 2005). This has led to the commercialisation of a number of 6 degree of freedom (DoF) systems using passive IR reflectors either mounted on the couch, a bite block, a thermoplastic mask, or the body of the patient (Willoughby *et al* 2012, Lightstone *et al* 2005, Bova *et al* 1997). Stereoscopic in-room cameras are used to monitor the IR reflector position, acting as surrogate for the tumour position (Jin *et al* 2008, Willoughby *et al* 2012). In addition, systems such as the ExacTrac 6D (Brainlab) and Real-time Position Management (RPM) (Figure 1a) can be used for respiratory gating of extracranial sites. These positioning systems are connected to a 6 DoF couch and are capable of beam interruption and patient repositioning during treatment with sub-millimetre accuracy (mean and SD of error) (Willoughby *et al* 2012).



Figure 1: a) Varian respiratory gating system uses an infrared reflective marker. (Image provided courtesy of Varian) b) Align RT/OSMS is an optical surface monitoring device (image courtesy of Vision RT) (Vision RT, London, UK). c) Elekta Active Breathing Coordinator (ABC) uses a spirometer to monitor lung volume (Courtesy, Helen McNair). d) The Anzai pressure belt (Anzai Medical, Tokyo, Japan) monitors the abdominal circumference.

RPM geometric accuracy was verified against fiducial marker (FM) trajectories for lung, liver and pancreas patients (Li *et al* 2012) and for lung patients treated in deep-inspiration breath-hold (DIBH) with visual feedback (Scherman Rydhög *et al* 2017). For RPM-guided left-sided breast DIBH treatments using multiple reflectors, (Fassi *et al* 2018) reported a median residual 3D set-up error of 5.8 mm compared with kilovoltage (kV) images of implanted clips.

To reduce the internal-external correlation uncertainty, IR-based monitoring is often used in conjunction with x-ray monitoring as described in section 2.3. In addition, on True Beam linacs (Varian), the respiratory gating system can be used in tandem with the kV on-board imaging system (OBI) where kV imaging is used to verify the internal target anatomy at the beginning of the gated treatment window determined by the RPM signal. If the internal anatomy has changed, the treatment can be interrupted and the patient repositioned based on newly acquired volumetric imaging (Vinogradskiy *et al* 2018).

2.1.2. Surface monitoring

Optical surface monitoring uses one or multiple high definition (HD) cameras to map the patient's surface. AlignRT (Vision RT)(Figure 1b) uses three such room-mounted cameras while Catalyst (C-RAD, Uppsala, Sweden) uses two room-mounted cameras. These systems project structured light

1
2
3 patterns on the patient such that 6 DoF motion can be estimated (Willoughby *et al* 2012). Visible light
4 from in-room lighting, the reflectivity and colour of patients' clothing or skin tone can potentially
5 affect the accuracy of surface mapping (Willoughby *et al* 2012). During treatment, the real-time
6 detected patient surface can be compared with a reference surface, often obtained from the simulation
7 CT. Typically one or more subsets of the surface can be selected as a region of interest (ROI) and are
8 used to report the translation and rotation of the patient in real-time via registration to the reference
9 surface. This system can also replace skin tattoos for set-up and allow the use of less invasive fixation
10 devices for SRS (Li *et al* 2011a, Pan *et al* 2012, Hoisak and Pawlicki 2018). Some integrated systems
11 such as Vision RT are able to automatically trigger beam-hold when the current surface does not
12 match the reference surface. Re-positioning of the patient can be done in-room with immediate
13 feedback from the system to guide the optimal match without the need for x-ray imaging.
14
15

16 Extracranially, surface guidance for intrafraction monitoring was mainly used for breast DIBH
17 treatments (Tang *et al* 2014, Ma *et al* 2018). The main advantage of DIBH is the increased distance
18 between the target volume and the heart resulting in lower dose to the heart and therefore lower rates
19 of early toxicity (Zagar *et al* 2017). Using 3D surface mapping, (Betgen *et al* 2013) evaluated the
20 reproducibility of voluntary DIBH and found a systematic interfractional translation up to 5 mm.
21
22

23 2.1.3. *Other breathing surrogates*

24 The airflow in and out of the lungs can be monitored using a spirometer which, in turn, is used to
25 estimate the air volume inside the lungs at a given time point. The patient breathes through a
26 mouthpiece, less leakage-prone than a mask (Wong *et al* 1999) and wears a nose clip to ensure that all
27 the breathing occurs through the mouth (Hoisak *et al* 2004). In addition to the monitoring, a scissor
28 valve can be added and used to maintain the air volume at a chosen level, therefore enforcing a
29 breath-hold. This is known as active breathing control (ABC) and was first described by (Wong *et al*
30 1999). A version by Elekta, under the name active breathing coordinator (ABC) (Figure 1c) uses a
31 balloon valve which prevents air-flow when inflated. ABC has been used for liver (Eccles *et al* 2006),
32 left breast (Remouchamps *et al* 2003) and lung (McNair *et al* 2009) cancer patients. The main
33 limitations for the use of ABC is the need for patient compliance, coaching sessions and good
34 communication between the radiographer and the patient.
35
36

37 A thermistor measuring the air temperature may also be used to determine if the patient is inhaling or
38 exhaling (Kubo and Hill 1996).
39

40 Pressure systems detect respiratory motion via the varying pressure in a belt around the abdominal
41 section of the patient. The Anzai belt (Anzai Medical, Figure 1d) is part of a respiratory gating system
42 (Siemens) where a pressure sensor (30 mm diameter, 9.5 mm thickness) is inserted in the belt and
43 outputs a binary 5V signal to the linac depending on the gating window parameters.
44

45 2.2. **kV and MV x-ray imaging-based methods**

46 Image-based methods using kV and/or megavoltage (MV) x-ray imaging were a natural development
47 from the concept of IGRT extending the use of in-room imaging from pre-treatment to intratreatment.
48 As such, these methods represent a considerable body of work.
49

50 X-ray image-based methods come in different hardware configurations of stereoscopic or monoscopic
51 imaging (Figure 2a-c) and can be combined with external monitoring (section 2.3). Common to all
52 image-based methods is the need for image processing to retrieve the target position information from
53 the planar image or set of images. The latency of x-ray image-based methods includes the image
54 acquisition time and the processing time (Fledelius *et al* 2011).
55
56

57 2.2.1. *Marker implantation and real-time segmentation in kV and MV images*

58 Most commonly, high contrast implanted FM (Figure 3) act as surrogate for the tumour position due
59 to poor soft tissue contrast. FM (Figure 3a) are routinely implanted in the prostate for pre-treatment
60

image guidance but may also be implanted percutaneously in the liver, pancreas and lungs or bronchoscopically in the peripheral lung (Shirato *et al* 2007) and in mediastinal lymph nodes (Schmidt *et al* 2016). Endoscopic implantation is possible into or near the digestive tract (Fukada *et al* 2013) while spinal and paraspinal lesion implantations are performed surgically (Shirato *et al* 2007). Endovascular coils have also been used as markers for lung tumours (Prévost *et al* 2008). Thinner markers that can take an irregular shape (Figure 3b) may be preferred to regularly shaped markers to limit artefacts in reconstructed volumetric images or the risk of migration or implantation complication (Hanazawa *et al* 2017, Castellanos *et al* 2018). Liquid FM such as Lipiodol (Guerbet, France) (Rose *et al* 2014) or BioXmark (Figure 3c) allow for a personalized injected volume, reduced artefacts in reconstructed volume images and reduced dose perturbation for particle therapy at the cost of lower contrast in x-ray projection images.




Figure 2: Systems for internal motion monitoring during RT delivery are shown. a) Elekta (Elekta AB, Stockholm Sweden) (top, image courtesy of Elekta) and Varian (Varian Medical Systems, Palo Alto, CA) (bottom, image provided courtesy of Varian) standard linacs with a deployed MV imager opposite the treatment head and a perpendicularly mounted kV imaging system. b) BrainLab ExacTrac (BrainLab AG, Feldkirchen, Germany) with stereoscopic kV imaging and external breathing monitoring (top, here mounted on an Elekta linac) and the RT-RT system with four kV imaging systems (bottom, reproduced from <https://rad.med.hokudai.ac.jp/en/research/treatment/tracking/> with permission) c) The robotic CyberKnife® (Accuray Inc, Sunnyvale, CA) system and Vero Gimbal (BrainLab and Mitsubishi Heavy Industries, Japan) incorporate stereoscopic kV imaging and external breathing monitoring. d) Unity (top, image courtesy of Elekta) and MRIdian (Viewray Inc, Cleveland, OH) (bottom) are the two commercially available MR-guided linacs (see section 2.5).

For any treatment guidance or adaptation based on intrafraction monitoring, markers must be segmented automatically in real-time, which is more difficult in MV images that have inherently lower contrast than kV images (Mao *et al* 2008, Lin *et al* 2013) and may have markers close to or outside the field edge (Hunt *et al* 2016, Poulsen *et al* 2014, Fledelius *et al* 2014). MV scatter onto the kV imager may also degrade the kV image quality (Fledelius *et al* 2014, Luo *et al* 2008) but can be efficiently reduced using triggered read-out to eliminate the accumulated MV scatter before each kV image acquisition (Poulsen *et al* 2015a).

Cylindrical or spherical markers can be segmented in real-time in kV or MV projections using simple parametric templates (Fledelius *et al* 2014, Mao *et al* 2008, Tang *et al* 2007, Marchant *et al* 2012). Arbitrarily shaped markers or marker groups require more complex templates that can be generated semi-automatically using breath-hold computed tomography (CT) scans (Regmi *et al* 2014) or fully automatically using pre-treatment CBCT projections (Bertholet *et al* 2017, Campbell *et al* 2017b). The segmented marker position is typically selected as the one with the highest normalized cross-correlation coefficient between the 2D template and a pre-defined ROI of the projection. There will always be a maximum in the normalized cross-correlation hence causing segmentation error if the marker is outside of the ROI. A larger ROI increases the chances that the marker is inside the ROI, but the computation time increases linearly with the ROI area and the template area, and a larger ROI increases the risk of mistaking the marker for some other structure in the image (Fledelius *et al* 2014). Suitable ROIs result in a typical processing time below 10 ms per marker per image (Fledelius *et al* 2014, Mao *et al* 2008). Low cross-correlation coefficients also allow to detect potentially erroneous

1
2 segmentation in template-based methods (Fledelius *et al* 2014, Tang *et al* 2007, Bertholet *et al* 2017)
3 (table 2).
4
5



19
20 *Figure 3: Examples of FM. a) 3 mm-long gold markers (civco, diameter between 0.8 and 1.2 mm) (top) can be implanted in*
21 *any soft tissue (middle) for image guidance. The similar 5x1 mm CyberMark™ was developed specifically for use with*
22 *CyberKnife® (bottom) (civco Radiotherapy, Coralville, IA). b) Gold anchor (Naslund Medical, Sweden) (diameter of 0.28 or*
23 *0.4 mm) (top) and Visicoils (IBA dosimetry, Barlett, TN) (diameter between 0.35 and 1.1 mm) (middle) take an arbitrary*
24 *shape once implanted (bottom). c) The liquid fiducial BioXmark (Nanovi, A/S, Denmark) before (top) and after endoscopic*
25 *assisted implantation (bottom).*

26 Template-free methods were also proposed using machine-learning with manually labelled data from
27 the first treatment fraction as training dataset (Lin *et al* 2013) or using a Dynamic Programming (DP)-
28 based method (Wan *et al* 2014, 2016). Due to the post-processing nature of the DP-based algorithm, it
29 has not been used in real-time to date. However, owing to the fast processing time, a pre-treatment
30 imaging data set could be acquired to initiate detection and intra-treatment images could be appended
31 to the data set as they are acquired for real-time segmentation.
32

33 Table 2: Properties of the marker segmentation algorithms discussed in section 2.2.1.

Method	Marker shape	Site (patient number)	Image type	Template generation	Manual input needed	Automatic error detection
(Fledelius <i>et al</i> 2014)	Cylindrical	Liver (13)	CBCT, kV, MV	Automatic	No	Yes – rejected segmentation
(Mao <i>et al</i> 2008)	Spherical, Cylindrical	Prostate (5)	kV, MV	Automatic	No	No ¹
(Tang <i>et al</i> 2007)	Cylindrical	Liver (2)	kV	Automatic (from library)	Yes (initialization)	Yes – terminates segmentation
(Marchant <i>et al</i> 2012)	Cylindrical	Pancreas (2), prostate (1)	CBCT	Gaussian kernels	Yes (initialization)	No ¹
(Regmi <i>et al</i> 2014)	Arbitrary (Visicoil), Cylindrical	Pancreas (4), Gastrointestinal junction (6), lungs (1)	CBCT	From breath-hold CT	Yes (template generation pre-treatment)	No
(Bertholet <i>et al</i> 2017)	Arbitrary (Visicoil), Cylindrical	Thorax (12), Abdomen (28)	CBCT	Automatic	No	Yes – rejected segmentation
(Campbell <i>et al</i> 2017b) ²	Cylindrical marker group	Pancreas (15)	CBCT	Automatic	No	No ¹
(Lin <i>et al</i> 2013)	Cylindrical	Prostate (2)	MV	No	Yes (manual selection of training sample at fraction 1)	No
(Wan <i>et al</i> 2016) ²	Arbitrary (Visicoil, embolization coil), Cylindrical (Gold, Calypso)	Abdomen (34), Lung (5)	CBCT	No	No	No

¹ Methods designed to have a 100% detection rate, ² Not fully demonstrated in real-time

1
2
3 Table 2 summarizes the properties of selected methods. Note that accuracy results are not presented
4 here. A fair comparison of segmentation algorithms is particularly difficult given the variety of image
5 quality, marker type, treatment site, and ground truth data used for the evaluation.
6

7 FM and their implantation represent an added cost and toxicity risk. Percutaneous implantation was
8 linked to a risk similar to conventional percutaneous biopsy in lung, pancreas and liver (Kothary *et al*
9 2009) with pneumothorax as the most common complication. For trans-rectal implantation in the
10 prostate, the main risk is urinary tract infection. However, it may be minimized by the use of thin
11 markers requiring a small needle (Castellanos *et al* 2018). The use of markers also implies delays in
12 the treatment due to the implantation itself but also often a waiting time between implantation and
13 planning CT to let markers stabilize although a delay between implantation and planning CT was
14 found to be unnecessary in liver patients (Worm *et al* 2016). Other limitations include marker
15 migration and changes in the tumour position relative to the markers due to tissue deformations.
16 Especially in the liver where markers are often implanted outside of the tumour to avoid tumour
17 seeding during percutaneous implantation, an increased target-surrogate distance has been linked to a
18 reduced targeting accuracy (Seppenwoolde *et al* 2011). For transbronchial implantation in the lungs,
19 (Ueki *et al* 2014) reported a residual intrafractional variation of the tumour position with respect to
20 the markers of 1.5 mm in the SI direction. (Shirato *et al* 2007) reported on the Hokkaido group
21 experience in marker implantation in multiple sites with multiple techniques and reported successful
22 implantation in 90 of 100 lesions without any serious complication. They observed that there is a
23 learning curve among endoscopists regarding fixation rate for implantation in the bronchial tree and
24 that the relationship between the markers and tumour can change significantly after two weeks. To
25 avoid the risk, cost, and uncertainty related to the use of FM, markerless monitoring in kV and MV
26 images may be used for certain sites (section 2.2. and 2.3).
27
28

30 2.2.2. *Stereoscopic imaging methods*

31
32 Real-time x-ray imaging is limited to 2D localization information. Ideally, stereoscopic kV imaging is
33 used to determine the target position via triangulation with high accuracy. However, this requires
34 additional equipment.
35

36 *The CyberKnife® system:*

37
38 The CyberKnife® system (Figure 2c top) was developed for frameless cranial SRS radiosurgery in the
39 1990s (Adler Jr. *et al* 1997) and shortly thereafter modified to treat extracranial sites (Murphy *et al*
40 2000). The system consists of two ceiling-mounted kV sources, two opposed floor-mounted flat panel
41 detectors (FPD) and automatic image processing software controlling a robotic 6MV-linac in real-
42 time. The robotic linac can re-align the treatment beam with 6 DoF in a non-isocentric manner,
43 therefore being the first dedicated treatment machine combining motion monitoring and tracking. The
44 system can monitor the target position with 6 DoF by co-registering two simultaneously acquired
45 intra-treatment radiographs to CT-generated digitally reconstructed radiographs (DRR). The first
46 clinical applications were for markerless monitoring for cranial SRS (Adler Jr. *et al* 1997) and for
47 cervical spine treatment in one patient (Murphy *et al* 2000). Cranium and spine are well suited for
48 markerless monitoring where the high contrast of the bony anatomy allows for confident registration.
49 Intratreatment radiographs can only be acquired every 10 or 20 seconds, which is insufficient to
50 resolve breathing motion. For respiratory motion, the x-ray monitoring is combined with continuous
51 optical monitoring as described in Section 2.3. Although insufficient to resolve respiratory motion,
52 stereoscopic imaging on the CyberKnife® system has been extensively used to monitor prostate
53 motion during SBRT (Friedland *et al* 2009, King *et al* 2012).
54
55

56 *The RTRT system*

57
58 High frequency intra-treatment stereoscopic imaging for monitoring was pioneered in the late 1990s
59 by (Shirato *et al* 1999) who installed an orthogonal x-ray imaging system in the treatment room of a
60 conventional linac creating the real-time tracking radiotherapy (RTRT) system (Shirato *et al* 2000).

Note that the RTRT system does not perform tracking in the sense of following the tumour with the treatment beam. Instead the position of a FM is monitored in real-time and the treatment beam is gated (Shirato *et al* 1999). The imaging part consists of four x-ray sources in the floor corners (superior right and left and inferior right and left), with corresponding ceiling-mounted detectors. The linac and the imaging system isocenters coincide and only two x-ray systems with unobstructed views are used at a time. The linac and the kV imaging system pulses are synchronized such that the kV images are free from MV scatter. Thirty kV image pairs are acquired per second and used to detect a spherical or Visicoil (Hanazawa *et al* 2017) FM using a simple template matching algorithm. Beam interlocks are set if the cross-correlation coefficient is too low or if the line of sight of the marker in the two imagers are further apart than 1.5 mm. The high monitoring rate of the RTRT system has permitted to extensively study tumour motion in various anatomical sites (Shirato *et al* 2007, Seppenwoolde *et al* 2002, Kitamura *et al* 2003, 2002, Kinoshita *et al* 2008, Ahn *et al* 2004, Hashimoto *et al* 2005).

(Shiinoki *et al* 2017) proposed to incorporate an RTRT-like system on a Varian linac: the SyncTraX system where only two cameras are used but can be set at three possible positions to ensure unobstructed view. (Berbeco *et al* 2004) also proposed a prototype integrated radiotherapy imaging system (IRIS). Although IRIS was not used clinically, the idea of a gantry-mounted stereoscopic imaging system was later commercialized as the Vero system.

The Vero system:

The Vero system (Figure 2c bottom) was described by (Kamino *et al* 2006) and consists of an O-ring gantry with a small gimbals-supported linac head. Two kV sources and opposite FPDs are mounted in the O-ring gantry at 45° with respect to the treatment beam and an EPID panel allows beam's eye view (BEV) imaging. Pan and tilt of the gimbals as well as skew angle of the gantry allow the treatment beam to track targets affected by respiratory and cardiac motion. The Vero system is used to treat patients with real-time tumour tracking (RTTT) based on a hybrid monitoring method (see section 2.3). However, (Dhont *et al* 2017) used the 20 s stereoscopic imaging session (at 11 Hz) used for an external correlation model (ECM) building to investigate short and long-term variations in breathing induced motion for 19 lung and 18 liver lesions bearing one Visicoil marker each. Substantial intrafractional drift (SI) was observed for both treatment sites with mean \pm SD values of 4.1 ± 1.7 mm and 3.0 ± 1.2 mm for lung and liver lesions respectively. Note that the Vero system is no longer commercially available.

Markerless stereoscopic monitoring:

In addition to the XSight Lung application described in section 2.3, the other markerless monitoring application that has been clinically used is the work of (Mori *et al* 2016). They have used this approach to treat both lung and liver cancer patients, making this the first application of markerless monitoring for liver cancer. They use a stereoscopic imaging system to acquire a series of patient images throughout the respiratory cycle. Their markerless tumour monitoring method uses multi-template matching and machine-learning algorithms, template images and a machine-learning dictionary file. Learning is performed for each patient based on the pre-treatment images. Once a model has been built and verified, the model is applied to process the images in real-time to determine the tumour position. The markerless monitoring system derives the beam pause function of their carbon ion treatment beam, enabling gated treatment.

Combined kV/MV:

On a conventional linac, MV imaging may complement kV imaging for triangulation of the target position. However, due to the low contrast of MV imaging, pre-processing techniques are required. (Hunt *et al* 2016) proposed to combine MV digital tomosynthesis (DTS) with kV imaging during volumetric arc therapy (VMAT) for patients with prostate cancer using conventional linacs (Figure 2a). The method was evaluated in phantom experiments and for three prostate patients treated with

VMAT, each having three implanted cylindrical fiducials. MV images were acquired continuously at ~ 9.5 Hz and arcs between 2 and 7° were used for MV-DTS while kV images were acquired every 20° . MV-DTS reduces the visibility of out-of-plane objects such as bony anatomy, however, a greater arc may result in blurring of the fiducials due to prostate motion and therefore hinder marker visibility. Single MV images or MV-DTS were paired with the corresponding kV image, FM were segmented and their 3D positions were determined by triangulation. In patients, motion monitoring results were validated against manual FM selection in single MV images triangulated with the closest kV image (ground truth position). Marker detection failures increased with the span of the MV-DTS due to MLC leaves obstructions of the markers in the MV images. The total processing time for fiducial detection in a 4° MV-DTS was 1.1 s of which 0.6 s was the MV-DTS reconstruction time.

The authors addressed the marker detection failure in MV images by developing an automatic plan optimization strategy ensuring that at least one fiducial was always visible (Zhang *et al* 2016). Exposing one fiducial was feasible without loss of plan quality. The method has now been clinically implemented to treat more than 110 prostate patients with gating (Keall *et al* 2018b). The same group recently extended the method to markerless kV/MV lung tumour monitoring by registering kV and MV images to CBCT projections acquired at the same gantry angle (Zhang *et al* 2018).

2.2.3. Monoscopic imaging methods

KV monoscopic imaging:

On a standard linac, the kV imaging system is mounted perpendicularly to the linac head (Figure 2a). Algorithms are thus used to infer motion in the unresolved dimension. kV images have better contrast than MV images, allowing more reliable detection of the target (FM or tumours) position in real time. Furthermore, the kV field-of-view can be selected to cover the target independently of the treatment beam shape, and kV images may be acquired prior to treatment onset as a training dataset for model building and motion prediction.

When a point target is projected onto an x-ray imager it is known to be located somewhere on the ray line between the projection point and the x-ray source. Real-time monoscopic target localization in general uses the projected target position in a sequence of training images from different angles to establish a model that allows estimation of the unresolved target position along the ray line (and thus the 3D position) in a new image. The model is assumed to be constant over a certain time such that it can be established by partial information from training images acquired at different times.

A very simple model is to neglect the motion taking place in the unresolved direction. The unresolved target position in the current image can then be determined by triangulation as the position on the ray line of a training image that is closest to the ray line of the current image. The triangulation can include several training images, possibly with different weights and can be rejected if the ray line is more than a certain threshold distance from the ray line of the current image or other training images. This is the idea behind Sequential Stereo (Varian Medical System), which was recently used for online real-time 3D spine localization during VMAT SBRT delivery (Hazelaar *et al* 2018c).

Sequential Stereo (Van Sörnsen De Koste *et al* 2015) and similar methods (Regmi *et al* 2014) can be used in the presence of respiratory motion provided that training images at the same breathing phase and with ray lines sufficiently close to the current image are available for the triangulation. This requirement can be avoided, e.g. by assuming a confined 3D target trajectory defined by the mean 3D position in two (Park *et al* 2012) or more (Becker *et al* 2010) respiratory phases as estimated by back-projecting sets of phase-sorted training images. The unresolved position of the current image is then estimated as the position closest to the confined 3D target trajectory.

Another approach is to establish a 3D probability density function (PDF) for the target position from a sequence of training images and estimate the unresolved position of the current image as the expectation or maximum value of the 1D PDF along the ray line. One possibility is a 3D Gaussian PDF determined from the projected target positions by maximum likelihood estimation (Poulsen *et al*

2008a). Another possibility is a Bayesian approach, where the 3D PDF is a product of individual contributions from training images that have uniform probability distributions along the ray line and exponential decay away from the ray line (Li *et al* 2011b). The PDF based methods can be used for both respiratory motion and non-periodic motion such as prostate motion.

A drawback of PDF-based methods is that the 3D-PDF must be rebuilt periodically to capture the possible changes in the distribution of motion (correlation or covariance of the 3D motion). The Kalman filter approach can overcome this drawback by iteratively re-estimating the posteriori function without solving all the parameters of the PDF (Kalman 1960, Shieh *et al* 2017). The Kalman filter framework implicitly assumes a Gaussian distributions which is computationally more efficient than other probabilistic approaches.

For respiratory motion, another approach is to exploit interdimensional motion correlation to model the unresolved LR and AP target positions as a function of the resolved SI position (Chung *et al* 2016). The parameters of the correlation model are fitted to the training images in an iterative way to account for the position dependent scaling factor between room coordinates and imager coordinates. When the correlation model is established, the full 3D position of the current image is estimated from the observed SI position. When an external respiratory signal is available a related approach is to establish an ECM of the target position along all three axes as function of the respiratory signal (Cho *et al* 2010) (see section 2.3).

A direct comparison between the different monoscopic methods is difficult since the performance depends on several factors such as the image sequence, motion trajectory, and possible model parameters. However, a recent comparison reported that the Gaussian and Bayesian PDF, the Kalman filter and the interdimensional motion correlation methods all had sub-millimetre accuracy (mean and SD of error) with the Gaussian PDF methods being the most precise (Montanaro *et al* 2018). One important limitation of this work is that segmentation, hence, 2D target information, was assumed to be perfect. In the presence of noise and segmentation errors, lower accuracy is expected.

The mostly widely used method is Kilovoltage Intrafraction Monitoring (KIM) which integrates the Gaussian PDF method for 3D motion estimation with template-based marker segmentation and has been used both retrospectively (Ng *et al* 2012) and prospectively (Keall *et al* 2015) for prostate cancer patients. In addition, similar systems were used to retrospectively estimate intrafraction motion of liver tumours for VMAT treatments (Poulsen *et al* 2014) and pancreas tumours in daily CBCT (Jones *et al* 2015). For these clinical applications, the tumour location is implicitly inferred by calculating the positions of the implanted gold FM. KIM accuracy has so far been evaluated against post-treatment triangulation, reporting sub-millimetre accuracy (mean and SD of error) in both retrospective analysis (Ng *et al* 2012) and prospective motion monitoring with beam gating and couch-shifts (Keall *et al* 2016). Recently, the KIM system has been extended for six degrees of freedom (DoF) motion monitoring in prostate patients (Nguyen *et al* 2017b). Measurements with a phantom show that sub-millimetre and sub-degree accuracy can be achieved for both prostate and lung motion traces (Kim *et al* 2017). In future applications, this can be replaced by direct 6 DoF motion estimation from 2D projection data to avoid the intermediary 3D estimation step (Nguyen *et al* 2017a). To date, more than 120 prostate patients have been treated with KIM monitoring.

Markers implanted into or adjacent to the tumour give the treatment team high confidence in the treatment targeting. However, as discussed in section 2.2.1, markerless approaches are highly desirable to avoid the added cost, risk and geometric uncertainty related to the use of FM. Given the high-density contrast in the lungs where the lung tissue density is approximately 20% of the tumour and surrounding tissue density, lung cancers are an ideal area to explore with x-ray image guidance.

Early work by (Berbeco *et al* 2005a) used fixed angle kV beams for tumour position analysis to determine when to gate the radiation beam. More recently a number of groups have developed sophisticated methods to determine the lung tumour position from these images (Lewis *et al* 2010,

Zhang et al 2014a, Ren et al 2014, Shieh et al 2017, Hazelaar et al 2018a). Though most of the work to date has been with single energy images, the ability to acquire dual energy x-rays can help with bone signal subtraction for enhanced soft tissue contrast (Patel et al 2015). Of note a recent study demonstrated bronchus monitoring on phantom and retrospective patient images (Hazelaar et al 2018d). Monitoring of the bronchus is interesting as it is an avoidance structure as well as a surrogate for the target position therefore allowing simultaneous tumour and normal tissue monitoring.

MV monoscopic imaging:

MV imaging using the treatment beam itself as a source and an electronic portal imaging device (EPID) is known as beam's eye view (BEV) imaging and does not add imaging dose to the patient. In addition, although MV BEV monitoring is not 3D, it does yield motion measurements in the two dimensions most sensitive to motion for photon radiotherapy, i.e. perpendicular to the treatment beam. However, MV imaging has poorer soft tissue and marker contrast than kV imaging, can only be used when the treatment beam is on, and the field of view is limited to the treatment beam and affected by the amount of beam modulation. BEV MV imaging was proposed both for marker and markerless monitoring.

In pioneering work, (Deutschmann et al 2012) used MV imaging of four markers implanted into the prostate to estimate the positional and rotational pose of the prostate and adapt the treatment accordingly. The prostate position was determined prior to each IMRT segment, and the segment positions for the IMRT treatment were adjusted accordingly without needing to adjust the couch position. To achieve this, a record-and-verify system with integrated treatment planning system had to be developed. This method was successfully applied in over 1000 fractions for 39 prostate cancer patients. The authors found over 2mm prostate drifts in 82% (833) of the fractions. Target rotation of >12 degrees was found for 10% of fractions. They concluded that the inter- and intrafraction motion measurements and adaptation enabled safe margin reduction. Though 2D motion measurements in BEV may be sufficient for photon radiotherapy applications, (Azcona et al 2013) applied a 2D to 3D trajectory reconstruction algorithm (Li et al 2011b) to the motion measured in clinical MV prostate images to establish the 3D target position during treatment.

MV BEV motion monitoring was experimentally implemented and demonstrated with MLC tracking for SBRT delivery in a pig with an implanted stent (Poulsen et al 2012a). In addition, it was used retrospectively for markerless monitoring on clinically acquired lung images (Richter et al 2010, Aristophanous et al 2011, Rottmann et al 2013).

2.2.4. Imaging dose

As reported in the AAPM TG75 report, a substantial limitation of kV imaging-based motion monitoring is the added imaging dose to the patient, especially at the skin surface (Murphy et al 2007). A kV image from a standard linac delivers 1-3 mGy per image depending on the technique. A total added imaging dose of 2-10 mSv was measured for KIM-guided prostate RT at 1Hz and, for comparison, the dose typically delivered by one pelvis CBCT scan was 4.3 mSv (Ng et al 2013). On the RTRT system (Shirato et al 2004) the skin dose from one fluoroscope was estimated to 29-1182 mGy/h and was highly dependent on kV peak and pulse duration but less so on skin-isocenter distance. Transient or main erythema can appear with an imaging dose of 2000 mGy or 6000 mGy respectively (Murphy et al 2007). Skin dose is therefore non-negligible for long IMRT treatments with the RTRT system. Depth dose at 5 cm was up to 58% of the peak dose and may also become a concern in IMRT treatments. Reduction of field size is an important but insufficient measure to reduce the dose, since the same area will receive the same skin dose every day. In a gantry mounted system, the source to detector distance is shorter than for the RTRT system which reduces exposure by a third compared to that of the RTRT system for a similar dose at the imager. The most direct way to reduce exposure remains reducing the imaging frequency as implemented in later generations of the RTRT system (Shirato et al 2004) or using hybrid monitoring.

2.3. Hybrid methods

Respiratory monitoring (section 2.1) is a poor surrogate for the position of internal targets (Li *et al* 2012, Hoisak *et al* 2004). To address this shortcoming, intrafraction imaging of FM may be used to verify external monitoring (see section 2.1.1). In addition, hybrid monitoring methods were developed specifically to combine respiratory monitoring with sparse imaging for internal monitoring. The general workflow includes a pre-treatment training phase of simultaneous internal and external monitoring where an ECM is built that relates the internal motion to the external motion. During treatment, the internal position is estimated from the external signal. Sparse imaging is used to verify the stability of the ECM and/or trigger an ECM update or rebuild if needed (see section 2.3.1). Figure 4 illustrates the kV geometry and gives a schematic overview of the pre-treatment model building and intra-treatment monitoring on the various platforms. Note that in all cases, the external monitoring (not shown on Figure 4) is provided by ceiling mounted cameras and reflective or emitting markers on the patient chest and/or abdomen (section 2.1).




Figure 4: Schematic overview of the geometry, pre-treatment model building and intra-treatment monitoring for the hybrid monitoring platforms. Note that the ExacTrac kV imaging system is non-coplanar at 60° angle (Figure 2b) and the MV source of the CyberKnife® can move non-isocentrically.

The CyberKnife® Synchrony system:

In addition to the robotic linac and kV imaging system of the CyberKnife® system (see section 2.2.2), Synchrony comprises a vest fitted with light emitting diodes (LED) markers and three ceiling-

1
2
3 mounted cameras to monitor external motion at 20-40 Hz (Ozhasoglu *et al* 2008). Prior to treatment,
4 at least eight x-ray pairs are acquired at different breathing phases (including end-inhale and end-
5 exhale) and used to triangulate the fiducial marker positions (Figure 4a). The external motion is
6 continuously recorded, and an ECM is built that relates the internal FM motion to the external marker
7 motion (see section 2.3.1). During treatment, the ECM is used to infer the marker positions and re-
8 align the treatment beam. In addition, new x-ray pairs can be acquired about every 30 seconds to
9 directly determine the FM positions by triangulation. The model can be updated on the fly in case of
10 small error or completely rebuilt using a new set of eight x-ray pairs after treatment interruption.
11
12

13 (Hoogeman *et al* 2009) analysed the log files for the treatment of 44 lung cancer patients on the
14 CyberKnife® Synchrony system and calculated the correlation error as the difference between the
15 estimated target positions and the actual target position in the intra-treatment images. They found a
16 sub-millimetre population mean error (mean of the SDs) in each direction and no difference in
17 correlation model error between centrally or peripherally located tumours.
18

19 (Bibault *et al* 2014) reported on markerless lung tumour monitoring using the Synchrony system for
20 51 patients. The method is known as Xsight Lung Tracking System and allows to use the DRR
21 method (see section 2.2.2) for lung tumours larger than 15 mm located in the apex and peripheral lung
22 region and further than 15 mm away from major vessels and ribs. Another detectability criterion was
23 that the projection of the tumour onto the spine must be at an angle different from 45°.
24

25 *The ExacTrac system:*

26 The ExacTrac system (Figure 2b, Figure 4b) combines an IR camera system with two floor-mounted
27 kV sources and opposite ceiling-mounted detectors (Willoughby *et al* 2006a). Between five and seven
28 external IR reflective markers are placed on the patient and detected by ceiling-mounted cameras (see
29 section 2.1.1). An IR reflective star is placed on the couch and used for automatic couch adjustments.
30 During treatment, when the external signal matches the reference gating level, an x-ray image pair is
31 acquired and the 3D triangulated position of a FM is compared with its reference position. If there is a
32 discrepancy larger than a set tolerance, the beam is switched off and the couch position is adjusted.
33 (Willoughby *et al* 2006a) and (Verellen *et al* 2006) reported on the initial clinical experience with 11
34 and three lung cancer patients respectively. A 6D fusion option was later implemented to allow 6 DoF
35 localization from the kV imaging system (Jin *et al* 2008).
36
37

38 In cranial SRS, reflective IR markers placed on a thermoplastic mask may be used for intrafraction
39 monitoring (see section 2.1.1). However, the masks are slightly elastic and patients may still move
40 within the mask. On the ExacTrac system, x-ray pairs can be acquired and 6DoF position correction is
41 obtained by 2D/3D image registration with planning DRRs. Radiograph pairs can be acquired for
42 verification pre- and post-treatment (Gevaert *et al* 2012)
43
44

The Vero system:

45 The Vero system described in section 2.2.2 includes an ExacTrac IR camera system. At the start of
46 treatment, simultaneous stereoscopic kV imaging at 11 Hz and external IR monitoring at 50 Hz are
47 performed in a 20-40 second training session to build an ECM (Figure 4c). During treatment, the
48 internal target position is determined from the ECM and stereoscopic images are acquired every 2
49 seconds. A ROI corresponding to a 3 mm tolerance radius around the predicted FM position is shown
50 and the user can decide to terminate the session if the tolerance is systematically exceeded. (Depuydt
51 *et al* 2014) reported on the first ten liver and lung SBRT patients treated on the Vero RTTT system.
52 The ECM building took an average of 2.7 min and was valid for an average (range) of 6.9 min (2.7 –
53 17.4 min). Significant cranial and posterior drift were observed for the IR and internal SI signal at the
54 beginning of treatment suggesting that the drift was due to patient relaxation. Following a similar
55 analysis for ten lung cancer patients, (Akimoto *et al* 2013) recommended frequent model updates to
56 avoid large baseline drift-related errors.
57
58

1
2
3 *RTRT with optical Anzai Belt:*
4

5 An RTRT system was installed at the Nippon Telegraph and Telephone corporation Hospital in
6 Sapporo, Japan. However, this system only had two kV imagers which may have an obstructed view
7 at certain gantry angles (Berbeco *et al* 2005b). The system was therefore supplemented by an external
8 optical system (Anzai Medical) using a laser source and detector on an extendable arm placed on the
9 treatment couch. (Berbeco *et al* 2005b) investigated the residual motion for eight lung cancer patients
10 treated with respiratory gating. Amplitude-based gating had slightly lower residual motion than phase-
11 based gating for irregular breathing. Beam-to-beam and day-to-day variations were observed that
12 warrant an adjustment of the gating window during the course of treatment, preferably based on
13 online internal imaging.
14

15 *COSMIK:*
16

17 (Bertholet *et al* 2018) implemented hybrid monitoring on a standard linac using Combined Optical
18 and Sparse Monoscopic Imaging with Kilovoltage x-rays (COSMIK, Figure 4d). The method was
19 developed as a hybrid alternative to KIM and therefore uses a similar monoscopic imaging technique
20 and the RPM (Varian) as external monitoring device. COSMIK uses a pre-treatment CBCT both for
21 patient set-up and as a training data set for ECM building. The FMs are automatically segmented in
22 the CBCT projections (Bertholet *et al* 2017) and their 3D trajectories are estimated using the Gaussian
23 PDF method (Poulsen *et al* 2008a). The 3D FM trajectories are used for automatic patient set-up
24 (Worm *et al* 2012) and to fit an augmented linear ECM (Ruan *et al* 2008). During treatment, the
25 internal FM positions are estimated from the continuous external signal using the ECM. kV images
26 are acquired every 3 seconds, the FMs are segmented and their 3D positions are estimated. The ECM
27 is updated based on the last three images for baseline drift between the internal and external signal.
28 COSMIK can be used for non-coplanar fields without imaging, using the latest updated ECM.
29 COSMIK was validated in phantom experiments and simulations and used on 14 liver SBRT patients
30 treated with implanted FM without motion mitigation. COSMIK was more recently combined with
31 real-time 4D dose reconstruction (Skouboe *et al* 2019, Raykilde *et al* 2018).
32

33 *2.3.1. Correlation models and update strategies*
34

35 Hybrid methods with ECM updates are more accurate than monitoring based on respiratory signals
36 alone (Poels *et al* 2014, Bertholet *et al* 2018, Malinowski *et al* 2013) but less accurate than continuous
37 kV imaging and they cannot be used to monitor non-correlated internal motion such as seen in the
38 prostate. Similar accuracy is achievable on specialized equipment and standard linacs because the
39 accuracy is limited by the use of an ECM rather than by the way (stereoscopic or monoscopic kV
40 imaging) that the ECM is being established (Cho *et al* 2010, Bertholet *et al* 2018). Despite the lower
41 accuracy related to the use of an ECM, hybrid monitoring presents certain advantages over continuous
42 kV imaging such as reduced imaging dose, shorter latency, continuous monitoring even during beam-
43 off time, robustness to missing or erroneous marker segmentation and compatibility with non-
44 coplanar treatment fields.
45

46 External/internal correlation and ECMs are therefore central to the use of hybrid methods. Several
47 studies have investigated the correlation between breathing and target motion, the stability of that
48 correlation, ECMs of different forms, and update strategies (McClelland *et al* 2013). The external
49 motion is often ambiguously related to the internal motion due to hysteresis where the same external
50 position results in different internal positions during inhale and exhale. Linear or quadratic models
51 cannot model hysteresis but may be combined with state augmentation using a time delayed sample
52 (Ruan *et al* 2008) or the first temporal derivative of the external position (Depuydt *et al* 2013).
53

54 On the CyberKnife® system, the hysteresis is addressed by using two quadratic functions without
55 state augmentation: one for the inhale phase and one for the exhale phase (Seppenwoolde *et al* 2007).
56 However, if the external motion exceeds the value observed during model building, a linear function
57 is used to avoid large errors due to quadratic extrapolation. During the training phase, linear as well as
58

1
2
3 dual quadratic models are fitted in each direction of motion. The model with the smallest DoF-
4 adjusted error is selected. As a result, the selected model may be linear in some directions of motion
5 and quadratic in others. Because several external signals are used, the information from the different
6 external markers can also be weighted using the Partial Least Square (PLS) method, thus eliminating
7 latent variables that do not contribute to the accuracy of the model (Malinowski *et al* 2012).

8 (Malinowski *et al* 2013) also investigated the effect of model updates on targeting accuracy using two
9 statistical metrics based on the external signal alone which resulted in a similar accuracy as updates
10 based on estimation errors but required fewer updates.

11 (Poels *et al* 2014) proposed a method for online model update on the Vero system where newly
12 acquired data points are used to replace old training data points at the same breathing phase
13 (determined by linear interpolation between exhale peaks). The accuracy improvement was significant
14 albeit very small between the clinical and online update strategies, however, the treatment time can be
15 reduced by about 5 minutes on average with the online update strategy compared to the clinical
16 update which requires treatment interruption to rebuild the model.

17 (Poels *et al* 2015) found similar performances for the CyberKnife® dual quadratic (CKDQ),
18 CyberKnife® linear and the Vero ECM on a same dataset from 15 liver and lung patients but due to
19 the complexity of the model, the latency of internal tumour motion estimation was 15 ms for the
20 CKDQ compared to 2 ms for the Vero model.

21 2.3.2. Future developments in hybrid motion monitoring and motion modelling

22 (Schnarr *et al* 2018) proposed to add a gantry-mounted kV imaging system perpendicular to the
23 treatment beam on the tomotherapy system (Accuray Inc.) to allow hybrid motion monitoring using
24 external optical monitoring combined with sequential monoscopic imaging.

25 Future software developments in hybrid motion monitoring include a 6D internal-external correlation
26 (6D-IEC) framework using monoscopic kV-imaging in a similar workflow as COSMIK for 6DoF
27 hybrid monitoring (Nguyen *et al* 2018).

28 Going one step further, one may want to monitor the motion of the entire anatomical region including
29 nearby OAR which may move differently from the target. Deformable motion models allow to
30 estimate the respiratory motion of the local 3D anatomy from limited surrogate data that can be
31 acquired during treatment (McClelland *et al* 2013). The surrogate data is often one or more external
32 breathing signals (see section 2.1) and the model is similar to an ECM, but can estimate the full
33 deformable motion of the local 3D anatomy. Methods have also been proposed that indirectly model
34 the relationship between the internal motion and the surrogate data, enabling the use of real-time 2D
35 imaging as surrogate data, such as kV-MV projection images (Vandemeulebroucke *et al* 2009) or 2D
36 cine MR images (Stemkens *et al* 2016) (see section 2.5). Such models have been very popular in the
37 research literature over the last 10-15 years (Meschini *et al* 2017, Thomas *et al* 2014, Wolfelschneider
38 *et al* 2017, McClelland *et al* 2013, Stemkens *et al* 2016), but to date have seen very limited clinical
39 use for two main reasons. Firstly, most methods require good quality 3D images which accurately
40 depict the respiratory motion in order to build the motion models. The majority of methods proposed
41 in the literature use 4DCT images for this purpose, however, 4DCT images only represent a single
42 breath-cycle and so cannot be used to accurately model variability in the breathing motion.

43 Furthermore, 4DCT images often contain sorting artefacts due to variable motion during acquisition
44 which cause inaccuracies and uncertainties in the motion models. Recently, methods have been
45 proposed that build the models from 4DMR datasets representing the 3D motion over several breath-
46 cycles and including breath-to-breath variability (Stemkens *et al* 2016). One drawback is that such
47 datasets can take a long time to acquire and process (Von Siebenthal *et al* 2007). Alternatively,
48 methods have been proposed that fit the motion models directly to unsorted partial or raw imaging
49 data, e.g. cine CT volumes, CT/MR slices (McClelland *et al* 2017), or CBCT projections (Martin *et al*
50 2014). Although promising, these methods still require further development and validation before

they are suitable for clinical use. The second issue that has so far prevented the clinical adoption of deformable motion models is the lack of methods to verify and update the motion models during treatment. One of the key features of the hybrid methods is the ability to intermittently verify and update ECMs against new imaging data during treatment (section 2.3.1). However, this is more challenging for deformable motion models, since it is not possible to obtain intermittent measurements of the full 3D motion during treatment. Future research will need to focus on developing methods that use intrafractional imaging data (e.g. 2D MR) to verify and update the models and to be sufficiently confident in the accuracy of the motion estimates.

2.4. Add-ons to standard equipment

Conventional linacs can be supplemented with add-on systems for motion monitoring. Respiratory and surface monitoring were discussed in section 2.1. SyncTraX and ExacTrac were discussed in sections 2.2.2 and 2.3. Here we discuss electromagnetic transponders (section 2.4.1, Figure 5a-b)), and ultrasound (section 2.4.2, Figure 5d). Note that motion monitoring using a radioactive implant (De Kruijf *et al* 2013) or emission guided radiotherapy (EGRT) based on positron emission tomography (PET) tracer detection (Fan *et al* 2012) have also been proposed. However, neither method is commercially available.




Figure 5: a) An anchored electromagnetic transponder (Calypso, Varian Medical Systems) (top) can be implanted transbronchially in the lungs while 17G beacons (top, below the anchored beacon) can be implanted in any soft tissue (middle). The system is completed by an in-room antenna and console (bottom). (image provided courtesy of Varian) b) Raypilot wired electromagnetic transponders (here shown uncoated, courtesy: Thomas Ravkilde) (top) can be implanted and removed from the prostate (middle) and plugged in a special couch (bottom) (Raypilot, Micropos Medical, Sweden). c) The Clarity Autoscan probe (Elekta) (top) and console (bottom)(image courtesy of Elekta)

2.4.1. Electromagnetic transponders/transmitters

Electromagnetic systems provide continuous real-time 3D localization of implanted transponders or transmitters without the use of ionizing radiation. The most commonly used system is Calypso (Varian Medical Systems), where the transponders are electromagnetic resonance circuits in sealed glass capsules (Balter *et al* 2005). Typically, three transponders with different resonance frequencies (300-500 kHz) are implanted in or near the treatment target. An array of excitation coils in a panel above the patient excites one transponder at a time while a second array of receiver coils localizes the resonating transponder by triangulation. It gives the 3D position of the transponder centroid relative to the panel with a frequency of 10-25 Hz. The position relative to the accelerator isocenter is determined by three room-mounted cameras that track infrared markers on the panel. Although the antenna panel causes changes in beam depth dose curves and beam attenuation, its dosimetric impact on clinical treatment plans was reported to be insignificant (Zou *et al* 2013).

Calypso was first used clinically in the prostate (Willoughby *et al* 2006b), where the ability of continuous monitoring without ionizing radiation has allowed systematic investigation of motion patterns (Kupelian *et al* 2007). Studies have revealed trends like strong cranial and anterior prostate motion correlation, increased likelihood of small to medium (>3-5 mm) prostate displacements with

time (but not of large displacements (>7 - 10 mm))(Langen *et al* 2008, Su *et al* 2011), as well as larger respiration induced prostate motion in prone position compared to supine position (Shah *et al* 2011, Butler *et al* 2013). Other clinical sites include the prostate bed following prostatectomy (Zhu *et al* 2013), pancreas (Shinohara *et al* 2012), and liver (Poulsen *et al* 2015b, Worm *et al* 2018, James *et al* 2016). In lung tissue, the stability of the smooth transponder is a challenge (Shah *et al* 2013) and an anchored version of the transponder with better attachment in the bronchia by five nitinol legs has been developed (Booth *et al* 2016, Schmitt *et al* 2017).

Drawbacks of the Calypso system include the requirement of a dedicated non-conducting couch top, lack of flexibility to move the installation between treatment rooms, a limited transponder detection volume extending maximum 21 cm below the antenna panel, and MR artifacts caused by the transponders (Zhu *et al* 2009). With a diameter of 1.85 mm (14 gauge implantation needle) the first generation of Calypso transponders were considerably larger than typical FM, but a thinner transponder for a 17 gauge needle is now available.

A similar system is RayPilot, which is an implantable wired radiofrequency transmitter that receives power through a wire from a couch top plate (Kindblom *et al* 2009, Vanhanen and Kapanen 2016). The couch top plate houses receiving antennas that detect the transmitter position and orientation at 30Hz. The transmitter is implanted transperineally in the prostate with the wire passing through the perineum of the patient, and it is removed after treatment completion. Recent clinical studies found that the implantation and explantation procedures were feasible and safe, but the studies also reported interfractional transmitter position instabilities and recommended to combine real-time prostate motion monitoring by RayPilot with an independent IGRT system for daily prostate localization (Braide *et al* 2018, Vanhanen *et al* 2018). A newer version of the RayPilot, HypoCath, is catheter-based to remove the need for surgical intervention and allows to localize the urethra as well as the prostate.

2.4.2. Ultrasound methods

Ultrasound (US) systems are capable of continuous image acquisition in real-time with good soft tissue contrast, while not exposing the patient to additional ionising radiation. This enables direct monitoring of internal tissue motion and deformation at high spatial and temporal resolutions. Clarity Autoscan™ (Elekta) (Figure 5d) is currently the only commercial US system designed for intrafraction motion monitoring. Approved specifically for prostate and prostate bed radiotherapy, the system incorporates a 3D transperineal US (TPUS) probe and is compatible with standard C-arm linacs. As such, Autoscan provides a flexible, cost-effective monitoring system that is unaffected by metal hip prostheses and does not require implanted FM. Integration with Elekta linacs enables motion mitigation via automated couch correction or gating, typically at an action threshold of 3 mm for 5 s, which can be varied if desired.

The US probe comprises a mechanically swept curvilinear transducer array with a 5 MHz centre frequency, which is secured to a baseplate to hold it in place during treatment. Sweeping the transducer array produces a continuously scanned 3D field of view. During monitoring, template matching based upon normalized cross correlation is used to automatically estimate the motion of a target reference volume within the imaging field of view (Lachaine and Falco 2013). The reference volume position is encoded in room coordinates by optically monitoring IR markers on the Autoscan probe using a room mounted stereoscopic camera (Polaris Spectra, NDI, Canada). Monitoring rates of ~0.5 Hz are employed for prostate motion monitoring.

Autoscan's accuracy was validated *in vivo* against manual localization of intraprostatic markers in EPID images (Grimwood *et al* 2018, Han *et al* 2018) and against Raypilot monitoring (Delcoudert *et al* 2017). Characterisations of prostate motion during treatment describe a gradual drift from the isocentre with substantial inter-patients variations showing maximum recorded shifts >10 mm and a mean SI drift of 0.075 mm/min (Ballhausen *et al* 2015, Li *et al* 2017).

1
2
3 As a soft tissue imaging modality, US is able to monitor a range of anatomical surrogates where the
4 lesion cannot be discerned. This has motivated the use of experimental ultrasound systems to study a
5 range of treatment sites beyond the prostate. The upper abdomen is of particular interest, because it is
6 susceptible to respiratory motion and is largely accessible to US without obstruction from bony
7 anatomy.
8

9 Liver motion monitoring using an adapted Vivid 7 Dimension probe (GE Healthcare, USA) was
10 evaluated against Calypso in a free-breathing patient immediately after liver SBRT (Ipsen *et al* 2017).
11 Another group has pioneered the use of an experimental version of Clarity to monitor the 3D position
12 of the liver in 13 patients during RT delivered in breath hold (Sihono *et al* 2017, Boda-Heggemann *et*
13 *al* 2016, Vogel *et al* 2018). A 3D US probe was held using a mechanical arm against the rib-cage
14 throughout planning CT, CBCT and RT delivery, without interfering with treatment delivery (Boda-
15 Heggemann *et al* 2016). The residual intra-breath-hold motion (e.g. drift) measured using US during
16 CBCT acquisition was found to correlate well with residual motion measured from CBCT projection
17 images (Vogel *et al* 2018).
18

19 US was also used for motion monitoring of the pancreatic head and surrogate structures, including the
20 superior mesenteric artery and portal vein (Omari *et al* 2016) as well as for diaphragm position
21 monitoring as a surrogate for lung tumour position (Mostafaei *et al* 2018).
22

23 US has been combined with MLC tracking *in vitro* (Fast *et al* 2016, Ipsen *et al* 2016) with a total
24 system latency of ~1 s, therefore demonstrating adequate compensation for the slow motion typically
25 observed in prostate cancer (Fast *et al* 2016, Colvill *et al* 2014). A predictive compensation method
26 was demonstrated on sinusoidal target movements, reducing system latencies to 172 ms (Ipsen *et al*
27 2016). This technique illustrates a potential approach to compensate for monitoring latency of
28 breathing motion in lung radiotherapy patients, but requires further *in vivo* evaluation.
29

30 Despite the scarcity of clinical free breathing patient studies, promising findings have also arisen from
31 the MICCAI Challenge on Ultrasound Liver Tracking (CLUST), which comprises an open dataset of
32 labelled anatomical features in 64 2D and 22 4D *in vivo* image sequences (De Luca *et al* 2018). Using
33 results from CLUST, an estimation of the impact from monitoring on treatment margins was made,
34 indicating a possible 75% reduction.
35


36 Optimal imaging requires careful probe placement to maximise patient-probe contact and to ensure
37 adequate anatomical coverage in the field of view. (Fargier-Voiron *et al* 2016, Li *et al* 2017) have
38 identified a need to control for anatomical deformation and changes to image quality associated with
39 variations in probe pressure. Furthermore, at patient set up, the probe must be manually adjusted to
40 ensure both reproducible positioning and adequate target volume coverage. Approaches to assist with
41 probe-positioning are being investigated (Camps *et al* 2017, 2018). Remote probe support and robotic
42 systems are also being developed to optimise probe placement during both patient set up and
43 treatment delivery (Schlosser *et al* 2012, Su *et al* 2017a, Sen *et al* 2017). The implications of placing
44 an ultrasound probe within the gantry arc require further consideration of the resulting beam
45 attenuation. Monte Carlo probe models have been developed for incorporation with planning software
46 (Bazalova-Carter *et al* 2015) and the integration of robotic ultrasound with the CyberKnife® system
47 has also been examined (Gerlach *et al* 2017). Another mitigation strategy has been pursued whereby a
48 probe was manufactured using radiolucent materials to reduce interference with the treatment beam
49 (Schlosser and Hristov 2016). Finally, an autonomous system for avoiding the treatment beam
50 altogether has also been demonstrated (Schlosser *et al* 2016).
51

52 **2.5. Magnetic Resonance imaging**

53 Recently, radiotherapy machines with integrated MR imaging have entered clinical practice (Paganelli
54 *et al* 2018). There are currently two commercially available MR-guided treatment systems: the
55 ViewRay MRIdian and the Elekta Unity system (Figure 2d) (Lagendijk *et al* 2014, Mutic and
56 Dempsey 2014, Mutic *et al* 2016, Raaymakers *et al* 2009). Additionally, two research groups operate
57

1
2
3 prototype systems (Keall *et al* 2014a, Liney *et al* 2016, Fallone 2014). The prospect of monitoring
4 intrafractional anatomical changes and guiding real-time adaptive radiotherapy with MR imaging was
5 one of the driving forces behind the development of these machines. MR imaging offers excellent
6 soft-tissue contrast and does not require FM implantation or expose the patient to additional imaging
7 dose. However, cancer patients with metal implants (e.g. prosthetics, pacemakers) or very large
8 patients cannot be examined using MR imaging.
9

10 It is not yet possible to acquire, reconstruct and postprocess 3D MR images at an adequate resolution
11 and imaging rate to monitor fast motion. Instead, 2D cine MR imaging, which is able to survey one or
12 multiple 2D imaging planes in real-time, may be harnessed to monitor fast-moving tumors and OAR.
13 Pioneered in cardiac imaging, cine MR imaging is usually based on gradient-echo MR sequences
14 deploying a single radiofrequency pulse (Bernstein *et al* 2004). This sequence design permits the use
15 of very short echo times and, consequently, shorter repetition times, resulting in sub-second
16 acquisitions. Varying these settings as well as adding additional sequence components, such as
17 preparation pulses, allows measurement of different image contrasts (Figure 6). In addition to
18 different contrasts, the image resolution, position and orientation may be adjusted. It is also possible
19 to successively survey multiple imaging planes in order to acquire some volumetric information. All
20 these imaging parameters influence the maximum imaging rate, typically in the order of a few images
21 per second. Additionally, scanner specifications, such as strength of the main and gradient magnetic
22 field and read-out electronics, impact the achievable contrast and acquisition speed.
23
24



41 *Figure 6: Two coronal 2D cine MR images of a lung cancer patient acquired with different gradient-echo MR sequences.*
42 *One has been acquired with a balanced steady-state free precession sequence providing a T2/T1-weighted contrast, while*
43 *the other was obtained using a spoiled gradient-echo sequence with a T1-weighted contrast (Menten *et al*, unpublished).*

44
45 Image acquisition can be further accelerated by reducing the amount of acquired k-space data. This
46 results in either a lower image resolution or a smaller field-of-view. Should neither be acceptable,
47 parallel imaging techniques can be deployed to reconstruct undersampled k-space data using multiple
48 independent coils to record the subject's MR signal (Deshmane *et al* 2012). As the signal measured by
49 each coil depends on its position relative to the patient, this additional spatial information can be used
50 during image reconstruction. It should be noted that the parallel imaging capabilities of most MR-
51 linac's are still limited. While diagnostic MR scanners with 32 or more individual coil channels are
52 commercially available, equivalent hardware is still lacking for MR-guided radiotherapy systems.
53

54 2D cine MR imaging can be used to either determine the tumor position directly or indirectly by
55 locating a surrogate structure whose movement is correlated with the target motion. In the future, it
56 may also be used to monitor target deformations and rotations as well as track nearby OAR.
57 Deformable motion models could also be used to estimate the local 3D anatomical motion from 2D
58 cine MR images, as discussed in section 2.3.2 (Stemkens *et al* 2016) (Tran *et al* 2018). Multiple
59 algorithms have been designed to accurately, reliably and quickly extract the position or outline of a
60

1
2
3 volume-of-interest from 2D cine MR images (Bourque *et al* 2016, Cerviño *et al* 2011, Feng *et al*
4 2016, Mazur *et al* 2015, Paganelli *et al* 2015, Shi *et al* 2014, Yip *et al* 2018, Yun *et al* 2015) with an
5 accuracy approaching inter-observer variability.
6

7 So far, most algorithms rely on a set of training contours from 2D cine MR images of the same
8 patient. In a clinical workflow, the training data can be collected as part of pre-treatment imaging and
9 reliable manual contours can be created while the patient is being prepared for treatment. Potentially,
10 algorithms trained on an independent cohort of patients could be used. Several papers have presented
11 promising segmentation tools for 3D biomedical images based on deep learning (Ronneberger *et al*
12 2015). However, this has not been explored yet for 2D cine MR imaging in a radiotherapy context.
13 Currently, obtaining a training dataset of sufficient size proves difficult as 2D cine MR images are
14 rarely acquired in clinical routine.
15

16 Localization accuracy in a 2D plane does not necessarily translate into usefulness to determine an
17 anatomical structure's position and extent in three dimensions. The volume-of-interest may shift
18 perpendicularly to the imaging plane or move out of it entirely. For this reason, multiple studies have
19 sought to optimize the number and orientation of 2D cine MR images for real-time adaptive
20 radiotherapy (Bjerre *et al* 2013, Brix *et al* 2014, Ipsen *et al* 2016, Menten *et al* 2018, Tryggestad *et al*
21 2013). While most of these studies show that 2D cine MR imaging can be used to localize a volume-
22 of-interest in three dimensions, no consensus strategy on image orientation and imaging parameters
23 can be derived from the literature. Both, the ideal imaging strategy and deployed image processing
24 may depend on the cancer site monitored as well as the desired intrafractional adaptation strategy.
25

26 MR guidance for intrafractional motion monitoring is still at its beginning. However, few clinics have
27 begun to deploy on-board MR imaging to guide intrafractional treatment beam gating on the ViewRay
28 MRIdian (Henke *et al* 2018, Green *et al* 2018, Tetar *et al* 2018). Gating with an average system
29 latency of 394 ms is based on a single sagittal 2D cine MR image acquired using a balanced steady-
30 state free precision sequence at four frames per second. At Washington University, St. Louis, MO,
31 USA, site of the first MR-guided treatment, approximately one third of patients undergoing MR-
32 guided radiotherapy are treated with gating (Fischer-Valuck *et al* 2017) mostly for the treatment of
33 thoracic and abdominal tumors. Results from initial clinical trials (Acharya *et al* 2016, Henke *et al*
34 2018) and further research studies will provide much needed experience about the potential of MR
35 imaging for intrafractional motion monitoring.
36

3. Validation and quality assurance

41 3.1. Validation tools for development and early implementation

42 A small number of studies have used animals for motion monitoring end-to-end testing (Shchory *et al*
43 2009, Poulsen *et al* 2012a). While animal experiments represent a realistic end-to-end test, they are
44 difficult to perform and may pose ethical concerns. In addition, ground truth motion is unknown in
45 animal subjects and experiments are not reproducible. End-to-end experiments using commercially
46 available moving phantoms allow reproducible testing of the technical components as well as to
47 evaluate the accuracy and the latency of intrafraction motion monitoring but they lack the realism of
48 human subjects in terms of image quality or complexity of motion.
49

50 (Malinowski *et al* 2007) proposed a motorized platform which can be used to move a rigid phantom or
51 dosimeter with high reproducibility (table 3). Anthropomorphic phantoms which provide a more
52 realistic representation of patient anatomy during end-to-end tests were also developed (Cheung and
53 Sawant 2015, Nioutsikou *et al* 2006, Kashani *et al* 2007, Perrin *et al* 2017, Remmert *et al* 2007,
54 Serban *et al* 2008, Steidl *et al* 2012, Haas *et al* 2014, Biederer *et al* 2006) with some representative
55 examples summarized in table 3. The representation of ribs is particularly important in thoracic
56 particle therapy since the presence (or absence) of a rib on the particle beam path may result in under
57 (or over-) shoot of the particle beam's Bragg peak. Detailed features such as vasculature and airways
58 are important for accurate deformable image registration in motion modelling. There is typically a
59

1
2
3 trade-off between realism/anthropomorphism and motion trajectory reproducibility and the use of
4 animal tissue requires careful expert manipulation and controlled laboratory conditions (Biederer and
5 Heller 2003). Highly realistic phantoms can also be generated using 3D printing technology although
6 this has been limited to static versions so far (Hazelaar *et al* 2018b).

7
8 Table 3: Physical phantoms developed by research group.
9

10 11 Phantom (site)	12 Deformable /Anthropomorphic	13 Motion reproducibility	14 Main features
15 WashU (any site) (Malinowski <i>et al</i> 2007)	16 No / No	17 • Target accuracy (mean \pm SD) < 1mm	18 • 3D axis and independent 1D vertical axis. 19 • Motorized platform to carry phantom or 20 dosimetry equipment
21 LuCa (lung) (Perrin <i>et al</i> 2017)	22 Yes (interior and exterior) / Yes (high level of detail)	23 • Stable end in/exhale (<1 mm). 24 • Tumour position varied 25 from day to day for a 26 given intermediary 27 in/exhale pressure.	28 • Inflatable/deformable lungs, skeleton, 29 muscles skin, solid heart, solid mobile 30 tumour (can hold dosimetric films). 31 • Motion actuated by an air pump inflating 32 the lungs. 33 • MR-compatible with visible deforming 34 lung features.
35 Lung (Cheung and Sawant 2015)	36 Yes (interior and exterior) / Yes (low level of internal detail)	37 • <2 mm day-to-day (ascribed to set-up) 38 • <0.25 mm RMS intra-day	39 • Deformable external shell 40 • Latex foam insert for lungs 41 • Rigid foam diaphragm actuated by the 42 WashU motion stage
43 Lung (Biederer <i>et al</i> 2006, 44 Remmert <i>et al</i> 2007)	45 Yes (interior) / Yes (animal heart and lungs, nodules, airways, no ribs)	46 • Maximal diaphragm displacement precision (SD) 1.90 mm (on CT), 1.47mm (on MR) 47 • Reproducibility of intermediary phases not quantified	48 • Porcine lung and heart explants with tracheal tube in saline solution, artificial pulmonary nodules 49 • Water-filled silicon diaphragm inflated or deflated by a water pump outside the MR room. 50 • MR-compatible
51 Lung (Serban <i>et al</i> 2008)	52 Yes (interior) / Yes (only one lung with vasculature/airways features)	53 • within image resolution (0.7 x 0.7 x 1.25 mm ³)	54 • Lung (natural latex balloon filled with damp sponges) in water, thoracic cavity (Lucite), diaphragm (motor-actuated piston), tumour (Dermasol ellipsoid), vascular and bronchial bifurcation (nylon wires and Lucite beads)
55 Lung (Steidl <i>et al</i> 2012)	56 Yes (exterior) / Yes (low level of internal detail, cubic tumour)	57 • Target accuracy (mean \pm SD) = 0 ± 0.09 mm (input vs log files)	58 • Artificial skeleton, rubber skin, 59 • Tumour: PMMA cube with 20 slots for pinpoint ion chambers and 5 films. 60 • Sternum-induced thoracic motion • 6D robot-actuated tumour motion independent of thoracic motion.
61 MAESTRO (lung) (Haas <i>et al</i> 2014)	62 Yes (ribcage only) / Yes (no vasculature)	63 • Millimetre positioning precision • Inter-cycle reproducibility <0.16 mm RMS	64 • Mechanically actuated ribs, stationary lungs, trachea and spine in hermetic skin (to be filled with water) • Robot-actuated tumour motion
65 ELPHA (liver) (Ehrbar <i>et al</i> 2019)	66 Yes (interior) / Yes (liver with vasculature)	67 • Reproducibility <0.32 mm RMS (inter- and intra-day)	68 • Soft silicon liver with vasculature (can hold dosimetric devices) • Static inferior plate and motor-driven superior plate • Ultrasound and CT contrast

69 Computer simulations are also an important part of validation for two main reasons: first, experiments
70 are time-consuming and simulations allow a larger data-set to be obtained providing better statistics
71

1
2
3 in a shorter time. Second, simulations allow comparison of various methods with perfect
4 reproducibility as well as exploration of other hardware configurations not necessarily available to the
5 user (Cho et al 2012, Bertholet et al 2018, Montanaro et al 2018). Digital phantoms may be
6 particularly useful for simulations involving multi-modality imaging (Segars et al 2010, Mishra et al
7 2012, Paganelli et al 2017). The XCAT phantom was based on visible male and female anatomical
8 datasets from the National Library of Medicine (Segars et al 2010, National Library of Medicine n.d.).
9 The heart motion model was derived from high resolution cardiac-gated multi-slice CT angiogram.
10 The breathing motion model was derived from respiratory gated-CT of healthy subjects and is
11 controlled by chest and diaphragm motion curves. The phantom has allowed other researchers to
12 closely reproduce tumour shape and location and motion seen in patients (Mishra et al 2012) and to
13 adapt it for MR imaging with detailed imaging parameters (Paganelli et al 2017). While state-of-the-
14 art digital phantoms can simulate realistic looking motion and images and are a valuable tool for
15 validation, it is not known how accurately the simulations represent the real motion that can occur in
16 human subjects, and they do not enable the end-to-end testing that can be performed with hardware
17 phantoms.
18
19

20 Motion traces used for simulations and experiments should also be carefully chosen. Site-specific
21 motion traces measured in patients should be used in generaly and internal traces should be preferred
22 to inferred traces especially for the validation of hybrid monitoring methods relying on internal-
23 external correlation or monoscopic imaging methods relying on inter-dimensional correlation
24 (Montanaro et al 2018).
25
26

27 Note that marker/tumour segmentation errors or uncertainties cannot be reproduced without patient
28 data and have to be assessed independently in retrospective clinical studies.
29

30 **3.2. Quality assurance**

31 An important limiting factor for the implementation of motion monitoring in clinical practice is the
32 uncertainty of QA procedures. Especially for combination with real-time adaption (tracking) where a
33 treatment plan validated pre-treatment is modified on the fly, standard patient-specific QA procedures
34 are no longer sufficient. The critical review by (De Los Santos *et al* 2013) and references herein
35 discuss the QA procedures specific to different motion monitoring and/or real-time adaptation
36 equipment. The AAPM TG-135 provides recommendations for QA of robotic radiosurgery (Dieterich
37 *et al* 2011), AAPM TG-154 provides recommendations on in-room US QA (Molloy *et al* 2011),
38 AAPM TG-104 provides recommendations for non-radiographic localization systems such as external
39 and electromagnetic methods (Willoughby *et al* 2012). For methods using linac mounted kV and MV
40 imaging, the regular linac commissioning methods described by AAPM TG-104 and AAPM TG-142
41 cover geometrical and image quality QA (Fang-Fang and John 2009, Klein *et al* 2009). To complete
42 the QA program for KIM, (Ng *et al* 2014) proposed additional tests based on the existing QA program
43 for the Calypso system (Santanam *et al* 2009). These tests included verification of the static
44 localization accuracy, the dynamic localization accuracy, the treatment interruption accuracy, latency
45 measurements and clinical conditions accuracy.
46
47

48 Important considerations for QA procedures are the latencies and geometric tolerances as well as the
49 frequency of the tests. (Ng *et al* 2014) chose a 1 mm geometric tolerance for the KIM QA program as
50 it is well below typical margins and in line with other geometric errors such as isocenters or couch
51 calibration. In order to set-up a program that is both efficient and effective, (Sawant *et al* 2010) used
52 the failure mode and effect analysis (FMEA) framework to determine the frequency of QA tests for
53 Calypso-guided MLC tracking. The industrial engineering FMEA framework consists of (i) charting a
54 process tree identifying each step of the procedure (in this case: motion monitoring and adaptation),
55 (ii) identifying the potential failure modes at each step, (iii) identifying the corresponding potential
56 causes and their downstream effects and, (iv) quantifying the overall risk of the failure based on the
57 probability of occurrence (O), severity of the effect (S) and detectability (D). O, S and D scores (from
58 1 to 10) can be multiplied to obtain the overall risk probability number (RPN). RPN scores were
59
60

1
2
3 obtained from a group of MLC tracking experts and tests for failure modes with a score above 125
4 were recommended to be performed monthly while other failure modes were recommended as part of
5 commissioning, annual quality assurance and after major hardware/software upgrades. The resulting
6 MLC tracking-specific QA program adds ~35 min to monthly QA and ~3.5 hours for comprehensive
7 testing.
8

9 For MR-linacs, interactions and interfacing of monitoring and treatment delivery tests have to be
10 performed in addition to conventional MR scanner and linac QA tests (Tijssen *et al* 2019). Hybrid
11 tests were therefore designed for aspects that are important to the RT-specific aspect of MR imaging
12 or that may be impacted by hardware modifications necessary to the integration of the two modalities.
13 In particular requirements for geometric fidelity on a large field of view are stricter for MR-guided
14 RT than for diagnostic MRI (Tijssen *et al* 2019, Ginn *et al* 2017). All QA tests need to be performed
15 with MR-safe and/or compatible equipment.
16

17 4. Translation to particle therapy

18 The translation of photon therapy motion monitoring concepts to particle therapy facilities was
19 mentioned in numerous publications (Shirato *et al* 2012, Riboldi *et al* 2012, Seco and Spadea 2015,
20 Kubiak 2016, Knopf *et al* 2016, Trnková *et al* 2018). However, only few studies have shown results
21 from such translations (Shimizu *et al* 2014, Umezawa *et al* 2015, Mori *et al* 2016). Efforts to translate
22 motion monitoring and motion mitigation approaches are challenged by stricter accuracy requirements
23 in particle therapy than in photon therapy. Particle dose distributions have a steeper dose fall-off at the
24 distal edge of the Bragg peak and are sensitive to inline anatomical changes. Furthermore, in particle
25 beam scanning (PBS), the interplay effect challenges the dose homogeneity for moving targets. As a
26 result, millimetre uncertainties can result in significant target dose miss or OAR overdosage.
27

28 Particle therapy facilities are nowadays equipped with similar in-room imaging capabilities as photon
29 therapy facilities (Figure 7). For patient positioning, orthogonal kV imaging was available early-on
30 (Figure 7a,b) and can potentially be used in fluoroscopy mode to track the movement of anatomical
31 structures or markers as suggested for the real-time-image gated, spot-scanning proton beam therapy
32 (RGPT) system at the Hokkaido University (Figure 7c)(Shimizu *et al* 2014, Umezawa *et al* 2015) or
33 for carbon-ion scanning (Figure 7d)(Mori *et al* 2016). A specific x-ray imaging implementation is
34 available at the Paul Scherer Institute (PSI), enabling BEV imaging (Figure 7e) (Pedroni 2006, Safai
35 *et al* 2012). (Zhang *et al* 2013) describe a method by which 3D motion can be extracted from such a
36 monoscopic, real-time imaging system. Optical surface imaging was introduced in proton therapy
37 facilities over the last years (Batin *et al* 2016) and showed to be more robust in monitoring respiratory
38 motion than electromagnetic monitoring in controlled laboratory conditions (Fattori *et al* 2017).
39 Furthermore, efforts are made towards hybrid motion monitoring system (Cho *et al* 2017) using
40 optical systems in combination with fluoroscopy systems. Optical imaging may have a more
41 important role to play in monitoring patient motion during particle therapy and respiratory motion
42 management than pre-treatment patient positioning when compared to volumetric CBCT/in-room CT
43 image guidance methods (Fattori *et al* 2016, Ciocca *et al* 2016). Clinical application of ultrasound
44 imaging in particle therapy has been rare, yet a phantom-based experiment has shown that real-time
45 ultrasound motion detection and beam tracking enable considerably reduced interplay effects in
46 scanned ion beam radiotherapy (Prall *et al* 2014).
47

48 Also, more and more studies about online MR-guided proton therapy have been published in the
49 recent years (Raaymakers *et al* 2008, Wolf and Bortfeld 2012, Moteabbed *et al* 2014, Hartman *et al*
50 2015, Oborn *et al* 2015, Fuchs *et al* 2017, Schellhammer *et al* 2018), envisioning new ways to enable
51 motion monitoring and mitigation. A recent review paper by (Oborn *et al* 2017) predicted the
52 accelerated development of hardware and simple prototype systems within a few years and coupled
53 systems integrated with gantries in a decade. For the time being, online MR-guided proton therapy
54 however remains a pure research topic far away from clinical implementation.
55

Despite the availability of imaging equipment, the provided information is often not sufficient to employ the same motion monitoring and motion mitigation concepts as for photon therapy. Surrogate motion information (e.g. from an implanted marker) might not be sufficient in particle therapy to guarantee target dose coverage. This is due to the sensitivity of particles not only to geometrical changes but also density changes along the beam path. Thus, to accurately assess the influence of motion on particle dose distributions, 4D anatomical images of the whole patient geometry within the beam path are required. Currently, mainly static targets are treated at proton therapy facilities. If at all, moving targets are treated in breath-hold or with gating (Minohara *et al* 2000, Bert *et al* 2009, He *et al* 2014, Zhang *et al* 2015, Yamada *et al* 2016). Tracking by steering the proton beam according to the target motion remains a research topic (Bert *et al* 2007, Grözinger *et al* 2008, Zhang *et al* 2014b).




Figure 7: Imaging during particle therapy. Gantry mounted CBCT systems on (a) the Varian probe beam (Image provided courtesy of Varian) or (b) the IBA system could be used in real-time fluoroscopy mode. Stereoscopic imaging was integrated with (c) proton beam scanning (reprinted from (Shimizu *et al* 2014) under CC BY licence.) and (d) carbon ion beam scanning (reprinted with permission from (Mori *et al* 2016)). (e) B x-ray imaging is available only at the PSI facility. The photo shows the x-ray tube mounted on the final bending magnet. (reprinted with permission from (Zhang *et al* 2013)).

Implanted FM are associated with specific particle therapy-related challenges requiring particular precaution (Kubiak 2016). Although commercially available markers are popular in photon radiotherapy, the feasibility of their direct implementation in particle therapy is still under investigation. In the PROMETHEUS trial carried out at the Heidelberg Ion Beam Therapy (HIT) Center, different markers were evaluated for suitability for the treatment of hepatocellular carcinoma using scanned ion beams (Habermehl *et al* 2013). A concern for the use of FM in particle therapy is that they are made of high-Z materials causing unfavourable artefacts in conventional CT scans (Schlosser *et al* 2010). The inaccurate representation of the electron density and thus Hounsfield units near the inserted clips may result in improper dose calculation (Habermehl *et al* 2013). Furthermore, metal markers can interact with particle beams (particularly scanned ion beams) and have a considerable impact on the therapy (Bert and Durante 2011). The degree of their influence on the dose

1
2
3 distribution, fluence and range of ions depends on the material, thickness and location in the treatment
4 field. Only thin markers (<0.5 mm) or those made of relatively low-Z materials, e.g. carbon-coated
5 zirconium oxide clips, may be considered for use in particle therapy (Habermehl *et al* 2013).

6 Electromagnetic localization of internal transponders is an alternative method of motion detection. At
7 PSI the TULOC system was developed and successfully tested (Seiler *et al* 2000) although it has not
8 been used clinically. An alternative implementation is the Calypso system described in section 2.4.1.
9 (Balter *et al* 2005). In their review, (Landry and Hua 2018) point out that electromagnetic monitoring
10 systems currently suffer from significant distortions which limit their use in a clinical particle therapy.
11
12

13 Precise motion monitoring is the premise for adaptive 4D particle therapy. Most publications agree
14 that the impact of motion in particle therapy (especially PBS) is highly individual for a specific set of
15 patient characteristics and machine parameters as well as their specific combinations per treatment
16 fraction. Thus, it is hard to predict dosimetric consequences of the tumour motion in prospective
17 multiple scenarios evaluations. More and more publications underline the value of log file based dose
18 reconstruction and accumulation to move towards 4D adaptive PBS particle therapy (Krieger *et al*
19 2018, Klimpki *et al* 2018, Pfeiler *et al* 2018). For such approaches, high-frequency, low-latency,
21 synchronized motion monitoring data is required. 4D-dose-accumulation treatment-assessment tools
22 are in the phase of clinical implementation (Meijers *et al* 2019), allowing for a quality assessment of
23 the 4D delivered dose throughout the treatment course triggering decisions for plan adaptations, in
24 case of significant deviations.
25

26 5. Conclusions and outlook

27 This review compared and analysed the different real-time motion monitoring methods that have been
28 clinically demonstrated. It illustrates the variety in hardware-focused methods (e.g. stereoscopic
29 imaging, dedicated tracking machines, MR-linac) and software-focused methods on standard-
30 equipped linacs (e.g. KIM, sequential stereo, COSMIK, kV/MV monitoring). Add-on equipment
31 represents a middle ground albeit also covering a spectrum between out-of-the-box systems (e.g.
32 Calypso) and more processing-intensive or user-dependant methods (e.g. ultrasound). In all three
33 categories, effort has been made to monitor soft tissues and tumours rather than internal or external
34 surrogates with the MR-linac as a dedicated machine, US as an add-on imaging technology and
35 markerless monitoring of lung tumours and bronchi on conventional linacs. However x-ray imaging is
36 limited by its inherently poorer soft tissue contrast than MR or US imaging. The choice of equipment
37 and method(s) to implement depends on three main factors. First: the treatment site. Respiratory
38 surrogate and hybrid monitoring for example are not applicable for prostate where gastro-intestinal
39 activity dominates organ motion. The strong reflection of ultrasound at tissue/air interfaces makes
40 ultrasound imaging a contraindication for direct lung tumour monitoring. Markerless x-ray based
41 monitoring is difficult in large patients as well as in the abdomen and pelvis due to poor contrast.
42 Second: the motion mitigation strategy. A high monitoring frequency may not be necessary for gated
43 prostate or spine treatments because of the slow motion. However, large excursion of the prostate due
44 to gas movement may require monitoring with a higher frequency in extreme hypofractionated
45 prostate RT. On the other hand, tracking tumours that move with respiration requires a high-frequency
46 low-latency signal in combination with prediction algorithms. Hybrid monitoring is well suited for
47 respiratory gating where kV imaging can be optimally used during MV beam-on time only. Latency
48 of motion monitoring methods are generally calculated indirectly from the entire real-time adaptation
49 system latency. The AAPM task group 76 report suggests that the total latency period of a real-time
50 tracking system should be kept as low as possible and below 0.5 s for respiratory motion because of
51 prediction algorithms limitations (Keall *et al* 2006). Given the slower motion of certain targets such as
52 the prostate or the spine, imaging rates and monitoring latencies of a second or more may be
53 acceptable for these targets. Similarly, baseline drift correction and tumour trailing for sites affected
54 by respiratory motion may not require a latency as low as 0.5 s. The third factor is material and human
55 resources. A specialized machine may be optimally used in large centres where a large volume of
56
57
58
59
60

1
2
3 patients justifies the investment and staff training. Smaller centres may prefer the versatility of
4 standard-equipped linac methods or mobile add-on equipment. FM or electromagnetic
5 transponder/transmitter implantation is also a complex procedure requiring specific
6 radiologist/bronchoscopist training and a good coordination in scheduling between different services.
7

8 This review also points out the variety of metrics used in reporting target motion amplitude and
9 motion monitoring accuracy. Percentile ranges are useful to determine ITV margins. Population mean
10 and SD of motion are often reported because they directly translate to random and systematic
11 component of margin calculation (van Herk 2004) while the RMS, also known as quadratic mean, is
12 less frequently reported. Yet, population-based measures do not adequately represent the variety in
13 individual motion patterns. The amount of time the target spends at a certain distance from its planned
14 position may also be useful to determine the margin robustness to motion. Different measures are
15 therefore pertinent to different sites and applications and can be reported on a population or on a per-
16 patient basis. In order to facilitate the comparison of motion monitoring reports, we recommend to
17 include population mean and SD for all directions of motion as well as the maximum mean and SD of
18 motion observed in a single patient and fraction to illustrate outlying but nonetheless realistic cases.
19

20 The accuracy of motion monitoring methods can be reported with similar measures as target motion.
21 BEV errors are sometimes reported instead of errors in each directions of motion. BEV errors may be
22 sufficient for photon therapy but inline errors should also be considered in particle therapy due to
23 range uncertainty. As mentioned in the introduction of section 2, accuracy is often defined as the
24 mean error which is not compliant with the ISO 5725-1 standard (ISO 1994). We recommend that
25 motion monitoring methods are described by their accuracy as the combination of the trueness (error
26 mean) and precision (standard deviation).
27

28 Motion mitigation is an obvious application of motion monitoring and several mitigation methods
29 have been compared in different treatment sites (Nankali *et al* 2018, Toftegaard *et al* 2017, Ehrbar *et*
30 *al* 2016, 2017a, Colvill *et al* 2016, Menten *et al* 2012). Another application of motion monitoring is
31 real-time dose reconstruction which can provide real-time QA for treatments delivered with or
32 without mitigation (Ravkilde *et al* 2014, 2018, Kamerling *et al* 2016a, 2017). Motion monitoring and
33 real-time dose reconstruction are the essential foundation of online replanning (Kontaxis *et al* 2017,
34 Kamerling *et al* 2016b). Motion-including dose reconstruction can also help to develop dose-response
35 models and evaluate clinical outcome based on the actually delivered dose instead of the planned dose
36 (Bentzen *et al* 2010, Meijers *et al* 2019, Siochi *et al* 2015).
37

38 IGRT – the integration of imaging and treatment in a single machine – revolutionized radiotherapy
39 and has opened “many doors for exploration” (Jaffray 2012). The exploration of x-ray based imaging
40 resulted in the clinical implementation of many methods discussed in this review and more
41 developments are still ahead (see section 2.2 and 2.3). Even more doors are now open with a new
42 form of IGRT: MR guidance. Progress in image processing and robotics may also facilitate wider
43 implementation of US imaging. Particle therapy puts higher demands on motion monitoring than
44 photon therapy. At modern proton facilities, almost the same imaging capabilities are nowadays
45 available as in photon therapy. If they will be employed in the same way in clinical routine remains to
46 be shown in the coming years.
47

48 The methods presented in this review were developed and implemented over about 20 years with
49 increasing level of surrogate quality and dimensionality. The state-of-the art has shifted from
50 respiratory surrogate monitoring, to single and to multiple implanted marker monitoring and
51 ultimately, imaging the tumour itself and/or the surrounding soft tissue with MR or US imaging. In
52 the same fashion, 1D breathing signals and 2D imaging were replaced by 3D inferred or triangulated
53 positions and 6 DoF monitoring while multiple object monitoring and motion models are aiming at
54 monitoring the position of the target and the surrounding organs which may move differently than the
55 target. This evolution shows that the community not only wants to “see what we treat as we treat” but
56 wants to see it in ever more detail. There is also a growing interest in performing functional imaging
57

1
2
3 during treatment (Datta *et al* 2018, Fan *et al* 2012). Functional imaging or the monitoring of
4 biological functions such as blood flow and cellular dynamics are not yet feasible in real-time in a
5 radiation therapy setting, and as such were considered beyond the scope of this review. However,
6 these effects likely play an important role in tumour control and toxicity effects of radiation therapy.
7 As well as the introduction of imaging in the treatment room (IGRT) paved the way to real-time
8 motion monitoring of tumour and OAR position, the introduction of functional imaging in the
9 treatment room is likely to open the way to real-time biology-guided radiation therapy.
10
11

Acknowledgements

12
13 JB, MM, JMC, BE, AG, EH and UO acknowledge funding by the Stand Up to Cancer campaign for
14 Cancer Research UK (C33589/A19727, C33589/A19908 and C20892/A23557) and the CRUK ART-
15 NET Network Accelerator Award (A21993). We acknowledge NHS funding to the NIHR Biomedical
16 Research Centre at The Royal Marsden and The Institute of Cancer Research. DTN acknowledge
17 funding from an Australian NHMRC Early Career Fellowship (ECF) and a Cancer Institute New
18 South Wales ECF. PK acknowledge funding from an Australian NHMRC Senior Principal Research
19 Fellowship. PP acknowledges funding from the Danish Cancer Society. The author's have confirmed
20 that any identifiable participants in this study have given their consent for publication.
21
22

Conflicts of interest

23
24 JB, MM, AG, EH and UO: The Institute of Cancer Research is part of the Elekta MR-linac Research
25 Consortium.
26
27

References

28
29 Acharya S, Fischer-Valuck B W, Kashani R, Parikh P, Yang D, Zhao T, Green O, Wooten O, Li H H,
30 Hu Y, Rodriguez V, Olsen L, Robinson C, Michalski J, Mutic S and Olsen J 2016 Online
31 Magnetic Resonance Image Guided Adaptive Radiation Therapy: First Clinical Applications *Int.*
32 *J. Radiat. Oncol. Biol. Phys.* **94** 394–403
33
34 Adler Jr. J R, Chang S D, Murphy M J, Doty J, Geis P and Hancock S L 1997 The Cyberknife: A
35 Frameless Robotic System for Radiosurgery *Stereotact. Funct. Neurosurg.* **69** 124–8
36
37 Ahn Y C, Shimizu S, Shirato H, Hashimoto T, Osaka Y, Zhang X Q, Abe T, Hosokawa M and
38 Miyasaka K 2004 Application of real-time tumor-tracking and gated radiotherapy system for
39 unresectable pancreatic cancer *Yonsei Med. J.* **45** 584–90
40
41 Akimoto M, Nakamura M, Mukumoto N, Tanabe H, Yamada M, Matsuo Y, Monzen H, Mizowaki T,
42 Kokubo M and Hiraoka M 2013 Predictive uncertainty in infrared marker-based dynamic tumor
43 tracking with Vero4DRT a) *Med. Phys.* **40** 091705
44
45 Aristophanous M, Rottmann J, Court L E and Berbeco R I 2011 EPID-guided 3D dose verification of
46 lung SBRT *Med. Phys.* **38** 495–503
47
48 Aubry J-F, Beaulieu L, Girouard L-M, Aubin S, Tremblay D, Laverdière J and Vigneault E 2004
49 Measurements of intrafraction motion and interfraction and intrafraction rotation of prostate by
50 three-dimensional analysis of daily portal imaging with radiopaque markers *Int. J. Radiat.*
51 *Oncol.* **60** 30–9
52
53 Azcona J D, Li R, Mok E, Hancock S and Xing L 2013 Automatic prostate tracking and motion
54 assessment in volumetric modulated arc therapy with an electronic portal imaging device *Int. J.*
55 *J. Radiat. Oncol. Biol. Phys.* **86** 762–8
56
57 Bainbridge H E, Menten M J, Fast M F, Nill S, Oelfke U and McDonald F 2017 Treating locally
58 advanced lung cancer with a 1.5T MR-Linac - Effects of the magnetic field and irradiation
59 geometry on conventionally fractionated and isotoxic dose-escalated radiotherapy *Radiother.*
60 *Oncol.* **125** 280–5

1
2
3 Ballhausen H, Li M, Hegemann N-S, Ganswindt U and Belka C 2015 Intra-fraction motion of the
4 prostate is a random walk *Phys. Med. Biol.* **60** 549–63
5
6 Balter J M, Wright J N, Newell L J, Friemel B, Dimmer S, Cheng Y, Wong J, Vertatschitsch E and
7 Mate T P 2005 Accuracy of a wireless localization system for radiotherapy *Int. J. Radiat. Oncol.*
8 *Biol. Phys.* **61** 933–7
9
10 Batin E, Depauw N, MacDonald S and Lu H M 2016 Can surface imaging improve the patient setup
11 for proton postmastectomy chest wall irradiation? *Pract. Radiat. Oncol.* **6** e235–41
12
13 Bazalova-Carter M, Schlosser J, Chen J and Hristov D 2015 Monte Carlo modeling of ultrasound
14 probes for image guided radiotherapy *Med. Phys.* **42** 5745–56
15
16 Becker N, Smith W L, Quirk S and Kay I 2010 Using cone-beam CT projection images to estimate
17 the average and complete trajectory of a fiducial marker moving with respiration *Phys. Med.*
18 *Biol.* **55** 7439–52
19
20 Bentzen S M, Constine L S, Deasy J O, Eisbruch A, Jackson A, Marks L B, Ten Haken R K and
21 Yorke E D 2010 Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): An
22 Introduction to the Scientific Issues *Int. J. Radiat. Oncol. Biol. Phys.* **76** 3–9
23
24 Berbeco R I, Jiang S B, Sharp G C, Chen G T Y, Mostafavi H and Shirato H 2004 Integrated
25 radiotherapy imaging system (IRIS): Design considerations of tumour tracking with linac
26 gantry-mounted diagnostic x-ray systems with flat-panel detectors *Phys. Med. Biol.* **49** 243–55
27
28 Berbeco R I, Mostafavi H, Sharp G C and Jiang S B 2005a Towards fluoroscopic respiratory gating
29 for lung tumours without radiopaque markers *Phys. Med. Biol.* **50** 4481–90
30
31 Berbeco R, Nishioka S, Shirato H, Chen G and Jiang S 2005b Residual Motion of Lung Tumors in
32 Gated Radiotherapy with External Respiratory Surrogates *Med. Phys.* **32** 2124
33
34 Bernstein M A, King K F and Zhou X J 2004 *Handbook of MRI Pulse Sequences*
35
36 Bert C and Durante M 2011 Motion in radiotherapy: particle therapy *Phys. Med. Biol.* **56** R113–44
37
38 Bert C, Gemmel A, Saito N and Rietzel E 2009 Gated Irradiation With Scanned Particle Beams *Int. J.*
39 *Radiat. Oncol. Biol. Phys.* **73** 1270–5
40
41 Bertholet J, Toftegaard J, Hansen R, Worm E S, Wan H, Parikh P J, Weber B, Høyer M and Poulsen
42 P R 2018 Automatic online and real-time tumour motion monitoring during stereotactic liver
43 treatments on a conventional linac by combined optical and sparse monoscopic imaging with
44 kilovoltage x-rays (COSMIK) *Phys. Med. Biol.* **63** 055012
45
46 Bertholet J, Wan H, Toftegaard J, Schmidt M L, Chotard F, Parikh P J and Poulsen P R 2017 Fully
47 automatic segmentation of arbitrarily shaped fiducial markers in cone-beam CT projections
48 *Phys. Med. Biol.* **62** 1327–41
49
50 Bertholet J, Worm E S, Fledelius W, Høyer M and Poulsen P R 2016 Time-Resolved Intrafraction
51 Target Translations and Rotations During Stereotactic Liver Radiation Therapy : Implications
52 for Marker-based Localization Accuracy *Int. J. Radiat. Oncol.* **95** 802–9
53
54 Betgen A, Alderliesten T, Sonke J-J, van Vliet-Vroegindeweij C, Bartelink H and Remeijer P 2013
55 Assessment of set-up variability during deep inspiration breath hold radiotherapy for breast
56 cancer patients by 3D-surface imaging *Radiother. Oncol.* **106** 225–30
57
58 Bibault J-E, Prevost B, Dansin E, Mirabel X, Lacornerie T and Lartigau E F 2014 Image-Guided
59 stereotactic body radiation therapy with Fiducial-Free tumor tracking for lung cancer *Radiat.*
60 *Oncol. 2012*, **7** 1–7
61
62 Biederer J and Heller M 2003 Artificial Thorax for MR Imaging Studies in Porcine Heart-Lung
63 Preparations *Radiology* **226** 250–5

1
2
3 Biederer J, Plathow C, Schoebinger M, Tetzlaff R, Puderbach M, Bolte H, Zaporozhan J, Meinzer H
4 P, Heller M and Kauczor H U 2006 Reproducible simulation of respiratory motion in porcine
5 lung explants *RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgeb.
6 Verfahren* **178** 1067–72

7
8 Bjerre T, Crijns S, Rosenschöld P M A, Aznar M, Specht L, Larsen R and Keall P 2013 Three-
9 dimensional MRI-linac intra-fraction guidance using multiple orthogonal cine-MRI planes *Phys.
10 Med. Biol.* **58** 4943–50

11
12 Boda-Heggemann J, Weiss C, Vogel L, Siebenlist K, Sihono D S K, Wertz H, Jahnke A, Simeonova-
13 Chergou A O, Ehmann M, Wenz F and Lohr F 2016 Ultrasound-Based Real-Time Tracking
14 During Abdominal Stereotactic Body Radiation Therapy: Ultrasound Probe Does Not Influence
15 Plan Quality Significantly *Int. J. Radiat. Oncol.* **96** E604–5

16
17 Booth J T, Caillet V, Hardcastle N, O'Brien R, Szymura K, Crasta C, Harris B, Haddad C, Eade T and
18 Keall P J 2016 The first patient treatment of electromagnetic-guided real time adaptive
19 radiotherapy using MLC tracking for lung SABR *Radiother. Oncol.* **121** 19–25

20 Bourque A E, Bedwani S, Filion É and Carrier J-F 2016 A particle filter based autocontouring
21 algorithm for lung tumor tracking using dynamic magnetic resonance imaging *Med. Phys.* **43**
22 5161–9

23 Bova F J, Buatti J M, Friedman W A, Mendenhall W M, Yang C C and Liu C 1997 The University of
24 Florida frameless high-precision stereotactic radiotherapy system *Int. J. Radiat. Oncol. Biol.
25 Phys.* **38** 875–82

26 Braide K, Lindencrona U, Welinder K, Götstedt J, Ståhl I, Pettersson N and Kindblom J 2018 Clinical
27 feasibility and positional stability of an implanted wired transmitter in a novel electromagnetic
28 positioning system for prostate cancer radiotherapy *Radiother. Oncol.* **128** 336–42

29 Brix L, Ringgaard S, Sørensen T S and Poulsen P R 2014 Three-dimensional liver motion tracking
30 using real-time two-dimensional MRI. *Med. Phys.* **41** 042302

31 Butler W M, Merrick G S, Reed J L, Murray B C and Kurko B S 2013 Intrafraction displacement of
32 prone versus supine prostate positioning monitored by real-time electromagnetic tracking *J.
33 Appl. Clin. Med. Phys.* **14** 198–208

34 Campbell W G, Jones B L, Schefter T, Goodman K A and Miften M 2017a An evaluation of motion
35 mitigation techniques for pancreatic SBRT *Radiother. Oncol.* **124** 168–73

36 Campbell W G, Miften M and Jones B L 2017b Automated target tracking in kilovoltage images
37 using dynamic templates of fiducial marker clusters *Med. Phys.* **44** 364–74

38 Camps S M, Fontanarosa D, Antico M, Edwards C, Dunnhofer M and Verhaegen F 2017 One-class
39 Gaussian process regressor for quality assessment of transperineal ultrasound images

40 Camps S M, Verhaegen F, Vanneste B G L, de With P H N and Fontanarosa D 2018 Automated
41 patient-specific transperineal ultrasound probe setups for prostate cancer patients undergoing
42 radiotherapy *Med. Phys.* **45** 3185–95

43 Case R B, Sonke J-J, Moseley D J, Kim J, Brock K K and Dawson L A 2009 Inter- and intrafraction
44 variability in liver position in non-breath-hold stereotactic body radiotherapy. *Int. J. Radiat.
45 Oncol. Biol. Phys.* **75** 302–8

46 Castellanos E, Wersäll P, Tilikidis A and Andersson A H 2018 Low Infection Rate After Transrectal
47 Implantation of Gold Anchor™ Fiducial Markers in Prostate Cancer Patients After Non-broad-
48 spectrum Antibiotic Prophylaxis *Cureus* **10** 1–9

49 Cerviño L I, Du J and Jiang S B 2011 MRI-guided tumor tracking in lung cancer radiotherapy *Phys.
50 Med. Biol.* **56** 3773–85

51 Chang J Y, Zhang X, Knopf A, Li H, Mori S, Dong L, Lu H M, Liu W, Badiyan S N, Both S, Meijers
52 A, Lin L, Flampouri S, Li Z, Umegaki K, Simone C B and Zhu X R 2017 Consensus Guidelines

1
2
3 for Implementing Pencil-Beam Scanning Proton Therapy for Thoracic Malignancies on Behalf
4 of the PTCOG Thoracic and Lymphoma Subcommittee *Int. J. Radiat. Oncol. Biol. Phys.* **99** 41–
5 50
6
7 Chen T, Qin S, Xu X, Jabbour S K, Haffty B G and Yue N J 2014 Frequency filtering based analysis
8 on the cardiac induced lung tumor motion and its impact on the radiotherapy management **112**
9 365–70
10
11 Cheung Y and Sawant A 2015 An externally and internally deformable, programmable lung motion
12 phantom *Med. Phys.* **42** 2585–93
13
14 Chi Y, Rezaeian N H, Shen C, Zhou Y, Lu W, Yang M, Hannan R and Jia X 2017 A new method to
15 reconstruct intra- fractional prostate motion in volumetric modulated arc therapy *Phys. Med.*
16 *Biol.* **62** 5509–30
17
18 Cho B, Poulsen P R and Keall P J 2010 Real-time tumor tracking using sequential kV imaging
19 combined with respiratory monitoring: a general framework applicable to commonly used IGRT
20 systems *Phys. Med. Biol.* **55** 3299–316
21
22 Cho B, Poulsen P, Ruan D, Sawant A and Keall P J 2012 Experimental investigation of a general real-
23 time 3D target localization method using sequential kV imaging combined with respiratory
24 monitoring. *Phys. Med. Biol.* **57** 7395–407
25
26 Cho J, Cheon W, Ahn S, Jung H, Sheen H, Park H C and Han Y 2017 Development of a real-time
27 internal and external marker tracking system for particle therapy: A phantom study using patient
28 tumor trajectory data *J. Radiat. Res.* **58** 710–9
29
30 Chung H, Poulsen P R, Keall P J, Cho S and Cho B 2016 Reconstruction of implanted marker
31 trajectories from cone-beam CT projection images using interdimensional correlation modeling
32 *Med. Phys.* **43** 4643–54
33
34 Ciocca M, Mirandola A, Molinelli S, Russo S, Mastella E, Vai A, Mairani A, Magro G, Pella A,
35 Donetti M, Valvo F, Fossati P and Baroni G 2016 Commissioning of the 4-D treatment delivery
36 system for organ motion management in synchrotron-based scanning ion beams *Phys. Medica*
37 **32** 1667–71
38
39 Colvill E, Booth J, Nill S, Fast M, Bedford J, Oelfke U, Nakamura M, Poulsen P, Worm E, Hansen R,
40 Ravkilde T, Scherman Rydhög J, Pommer T, Munck Af Rosenschold P, Lang S, Guckenberger
41 M, Groh C, Herrmann C, Verellen D, Poels K, Wang L, Hadsell M, Sothmann T, Blanck O and
42 Keall P 2016 A dosimetric comparison of real-time adaptive and non-adaptive radiotherapy: A
43 multi-institutional study encompassing robotic, gimbaled, multileaf collimator and couch
44 tracking *Radiother. Oncol.* **119** 159–65
45
46 Datta A, Aznar M C, Dubec M, Parker G J M and O'Connor J P B 2018 Delivering Functional
47 Imaging on the MRI-Linac: Current Challenges and Potential Solutions *Clin. Oncol.* **30** 702–10
48
49 Delcoudert L, Fargier-Voiron M, Munoz A, Pommier P and Biston M C 2017 7. Covalidation of the
50 performances of a transperineal ultrasound probe and electromagnetic transmitter for monitoring
51 prostate cancer motions in radiotherapy *Phys. Medica* **44** 4–5
52
53 Depuydt T, Poels K, Verellen D, Engels B, Collen C, Buleteanu M, Van Den Begin R, Boussaer M,
54 Duchateau M, Gevaert T, Storme G and De Ridder M 2014 Treating patients with real-time
55 tumor tracking using the Vero gimbaled linac system: Implementation and first review
56 *Radiother. Oncol.* **112** 343–51
57
58 Depuydt T, Poels K, Verellen D, Engels B, Collen C, Haverbeke C, Gevaert T, Buls N, Van Gompel
59 G, Reynders T, Duchateau M, Tournel K, Boussaer M, Steenbeke F, Vandenbroucke F and De
60 Ridder M 2013 Initial assessment of tumor tracking with a gimbaled linac system in clinical
circumstances: A patient simulation study *Radiother. Oncol.* **106** 236–40
61
62 Deshmane A, Gulani V, Griswold M A and Seiberlich N 2012 Parallel MR imaging *J. Magn. Reson.*
63 *Imaging* **36** 55–72

1
2
3 Deutschmann H, Kametriser G, Steininger P, Scherer P, Schöller H, Gaisberger C, Mooslechner M,
4 Mitterlechner B, Weichenberger H, Fastner G, Wurstbauer K, Jeschke S, Forstner R and
5 Sedlmayer F 2012 First clinical release of an online, adaptive, aperture-based image-guided
6 radiotherapy strategy in intensity-modulated radiotherapy to correct for inter- and intrafractional
7 rotations of the prostate *Int. J. Radiat. Oncol. Biol. Phys.* **83** 1624–32

8
9 Dhont J, Vandemeulebroucke J, Burghelea M, Poels K, Depuydt T, Van Den Begin R, Jaudet C,
10 Collen C, Engels B, Reynders T, Boussaer M, Gevaert T, De Ridder M and Verellen D 2017
11 The long- and short-term variability of breathing induced tumor motion in lung and liver over
12 the course of a radiotherapy treatment *Radiother. Oncol.* **126** 339–46

13
14 Dieterich S, Cavedon C, Chuang C F, Cohen A B, Garrett J A, Lee C L, Lowenstein J R, D’Souza M
15 F, Taylor D D, Wu X and Yu C 2011 Report of AAPM TG 135: Quality assurance for robotic
16 radiosurgery *Med. Phys.* **38** 2914–36

17
18 Dieterich S, Cleary K, D’Souza W, Murphy M, Wong K H and Keall P 2008 Locating and targeting
19 moving tumors with radiation beams *Med. Phys.* **35** 5684–94

20
21 Eccles C, Brock K K, Bissonnette J P, Hawkins M and Dawson L A 2006 Reproducibility of liver
22 position using active breathing coordinator for liver cancer radiotherapy *Int. J. Radiat. Oncol.*
23 *Biol. Phys.* **64** 751–9

24
25 Ehrbar S, Jöhl A, Kühni M, Meboldt M, Elsen E, Tanner C, Goksel O, Klöck S, Unkelbach J,
26 Guckenberger M and Tanadini-Lang S 2019 ELPHA: Dynamically deformable liver phantom
for real-time motion- adaptive radiotherapy treatments *Med. Phys.*

27
28 Ehrbar S, Perrin R, Peroni M, Bernatowicz K, Parkel T, Pytko I, Klöck S, Guckenberger M, Tanadini-
29 Lang S, Weber D C and Lomax A 2016 Respiratory motion-management in stereotactic body
30 radiation therapy for lung cancer - A dosimetric comparison in an anthropomorphic lung
phantom (LuCa) *Radiother. Oncol.* **121** 328–34

31
32 Ehrbar S, Schmid S, Jöhl A, Klöck S, Guckenberger M, Riesterer O and Tanadini-Lang S 2017a
33 Comparison of multi-leaf collimator tracking and treatment-couch tracking during stereotactic
34 body radiation therapy of prostate cancer *Radiother. Oncol.* **125** 445–52

35
36 Ehrbar S, Schmid S, Jöhl A, Klöck S, Guckenberger M, Riesterer O and Tanadini-Lang S 2017b
37 Validation of Dynamic Treatment-Couch Tracking for Prostate SBRT *Med. Phys.* **44** 2466–77

38
39 Engelsman M, Schwarz M and Dong L 2013 Physics Controversies in Proton Therapy *Semin. Radiat.*
40 *Oncol.* **23** 88–96

41
42 Fallone B G 2014 The Rotating Biplanar Linac-Magnetic Resonance Imaging System *Semin. Radiat.*
43 *Oncol.* **24** 200–2

44
45 Fan Q, Nanduri A, Mazin S and Zhu L 2012 Emission guided radiation therapy for lung and prostate
cancers: A feasibility study on a digital patient *Med. Phys.* **39** 7140–52

46
47 Fang-Fang Y and John W 2009 *The Role of In-Room kV X-Ray Imaging for Patient Setup and Target*
48 *Localization Report of AAPM Task Group 104*

49
50 Fargier-Voiron M, Presles B, Pommier P, Munoz A, Rit S, Sarrut D and Biston M C 2016 Evaluation
51 of a new transperineal ultrasound probe for inter-fraction image-guidance for definitive and
post-operative prostate cancer radiotherapy *Phys. Medica* **32** 499–505

52
53 Fassi A, Ivaldi G B, de Fatis P T, Liotta M, Meaglia I, Porcu P, Regolo L, Riboldi M and Baroni G
54 2018 Target position reproducibility in left-breast irradiation with deep inspiration breath-hold
55 using multiple optical surface control points *J. Appl. Clin. Med. Phys.* **19** 35–43

56
57 Fast M F, O’Shea T P, Nill S, Oelfke U and Harris E J 2016 First evaluation of the feasibility of MLC
58 tracking using ultrasound motion estimation *Med. Phys.* **43** 4628–33

59
60 Fattori G, Safai S, Carmona P F, Peroni M, Perrin R, Weber D C and Lomax A J 2017 Monitoring of
breathing motion in image-guided PBS proton therapy: Comparative analysis of optical and

1
2
3 electromagnetic technologies *Radiat. Oncol.* **12** 1–11
4

5 Fattori G, Seregni M, Pella A, Riboldi M, Capasso L, Donetti M, Ciocca M, Giordanengo S, Pullia M,
6 Marchetto F and Baroni G 2016 Real-time optical tracking for motion compensated irradiation
7 with scanned particle beams at CNAO *Nucl. Instruments Methods Phys. Res. Sect. A Accel.*
8 *Spectrometers, Detect. Assoc. Equip.* **827** 39–45

9 Feng Y, Kawrakow I, Olsen J, Parikh P J, Noel C, Wooten O, Du D, Mutic S and Hu Y 2016 A
10 comparative study of automatic image segmentation algorithms for target tracking in MR-IGRT
11 *J. Appl. Clin. Med. Phys.* **17** 441–60

12 Fischer-Valuck B W, Henke L, Green O, Kashani R, Acharya S, Bradley J D, Robinson C G, Thomas
13 M, Zoberi I, Thorstad W, Gay H, Huang J, Roach M, Rodriguez V, Santanam L, Li H, Li H,
14 Contreras J, Mazur T, Hallahan D, Olsen J R, Parikh P, Mutic S and Michalski J 2017 Two-and-a-half-year clinical experience with the world's first magnetic resonance image guided radiation
15 therapy system *Adv. Radiat. Oncol.* **2** 485–93

16 Fledelius W, Keall P J, Cho B, Yang X, Morf D, Scheib S and Poulsen P R 2011 Tracking latency in
17 image-based dynamic MLC tracking with direct image access. *Acta Oncol. (Madr.)* **50** 952–9

18 Fledelius W, Worm E, Høyer M, Grau C and Poulsen P R 2014 Real-time segmentation of multiple
19 implanted cylindrical liver markers in kilovoltage and megavoltage x-ray images. *Phys. Med. Biol.* **59**
20 2787–800

21 Friedland J L, Freeman D E, Masterson-McGary M E and Spellberg D M 2009 Stereotactic body
22 radiotherapy: an emerging treatment approach for localized prostate cancer. *Technol. Cancer
23 Res. Treat.* **8** 387–92

24 Fuchs H, Moser P, Gröschl M and Georg D 2017 Magnetic field effects on particle beams and their
25 implications for dose calculation in MR-guided particle therapy *Med. Phys.* **44** 1149–56

26 Fukada J, Hanada T and Kawaguchi O 2013 Detection of Esophageal Fiducial Marker Displacement
27 During Radiation Therapy With a 2-dimensional On-board Imager : Analysis of Internal Margin
28 for Esophageal Cancer *Radiat. Oncol. Biol.* **85** 991–8

29 Gerlach S, Kuhleman I, Ernst F, Fürweger C and Schlaefer A 2017 Impact of robotic ultrasound
30 image guidance on plan quality in SBRT of the prostate *Br. J. Radiol.* **90**

31 Gevaert T, Verellen D, Engels B, Depuydt T, Heuninckx K, Tournel K, Duchateau M, Reynders T
32 and De Ridder M 2012 Clinical evaluation of a robotic 6-degree of freedom treatment couch for
33 frameless radiosurgery *Int. J. Radiat. Oncol. Biol. Phys.* **83** 467–74

34 Ghilezan M J, Jaffray D A, Siewersen J H, Van Herk M, Shetty A, Sharpe M B, Zafar Jafri S, Vicini
35 F A, Matter R C, Brabbins D S and Martinez A A 2005 Prostate gland motion assessed with
36 cine-magnetic resonance imaging (cine-MRI) *Int. J. Radiat. Oncol.* **62** 406–17

37 Ginn J S, Agazaryan N, Cao M, Baharom U, Low D A, Yang Y, Gao Y, Hu P, Lee P and Lamb J M
38 2017 Characterization of spatial distortion in a 0.35 T MRI-guided radiotherapy system *Phys.
39 Med. Biol.* **62** 4525–40

40 Glitzner M, Woodhead P L, Lagendijk J J W and Raaymakers B W 2018 OC-0189: First MLC-
41 tracking on the 1.5T MR-linac system *Radiother. Oncol.* **127** S101–2

42 Green O L, Rankine L J, Cai B, Cururu A, Kashani R, Rodriguez V, Li H H, Parikh P J, Robinson C
43 G, Olsen J R, Mutic S, Goddu S M and Santanam L 2018 First clinical implementation of real-
44 time, real anatomy tracking and radiation beam control *Med. Phys.* **45** 3728–40

45 Grimwood A, McNair H A, O'Shea T P, Gilroy S, Thomas K, Bamber J C, Tree A C and Harris E J
46 2018 In Vivo Validation of Elekta's Clarity Autoscan for Ultrasound-based Intrafraction Motion
47 Estimation of the Prostate During Radiation Therapy *Int. J. Radiat. Oncol. Biol. Phys.* **102** 912–
48 21

49 Grözinger S O, Bert C, Haberer T, Kraft G and Rietzel E 2008 Motion compensation with a scanned
50

1
2
3 ion beam: A technical feasibility study *Radiat. Oncol.* **3** 1–7
4
5 Haas O C L, Mills J A, Land I, Mulholl P, Menary P, Crichton R, Wilson A, Sage J, Anna M and
6 Depuydt T 2014 IGRT/ART phantom with programmable independent rib cage and tumor
7 motion *Med. Phys.* **41** 022106
8
9 Habermehl D, Henkner K, Ecker S, Jäkel O, Debus J and Combs S E 2013 Evaluation of different
10 fiducial markers for image-guided radiotherapy and particle therapy *J. Radiat. Res.* **54** 61–8
11
12 Han B, Najafi M, Cooper D, Lachaine M, Von Eyben R, Hancock S and Hristov D 2018 Evaluation
13 of Transperineal Ultrasound Imaging as a Potential Solution for Target Tracking During
14 Ablative Body Radiotherapy for Prostate Cancer *Radiat. Oncol.* **13**
15
16 Hanazawa H, Takahashi S, Shiinoki T, Park S C, Yuasa Y, Koike M, Kawamura S and Shibuya K
17 2017 Clinical assessment of coiled fiducial markers as internal surrogates for hepatocellular
18 carcinomas during gated stereotactic body radiotherapy with a real-time tumor-tracking system
19 *Radiother. Oncol.* **123** 43–8
20
21 Hartman J, Kontaxis C, Bol G H, Frank S J, Lagendijk J J W, Van Vulpen M and Raaymakers B W
22 2015 Dosimetric feasibility of intensity modulated proton therapy in a transverse magnetic field
of 1.5 T *Phys. Med. Biol.* **60** 5955–69
23
24 Hashimoto T, Shirato H, Kato M, Yamazaki K, Kurauchi N, Morikawa T, Shimizu S, Ahn Y C,
25 Akine Y and Miyasaka K 2005 Real-time monitoring of a digestive tract marker to reduce
26 adverse effects of moving organs at risk (OAR) in radiotherapy for thoracic and abdominal
27 tumors *Int. J. Radiat. Oncol. Biol. Phys.* **61** 1559–64
28
29 Hazelaar C, Dahele M, Mostafavi H, van der Weide L, Slotman B and Verbakel W 2018a Markerless
30 positional verification using template matching and triangulation of kV images acquired during
31 irradiation for lung tumors treated in breath-hold *Phys. Med. Biol.* **63** 115005
32
33 Hazelaar C, Van Eijnatten M, Dahele M, Wolff J, Forouzanfar T, Slotman B and Verbakel W F A R
34 2018b Using 3D printing techniques to create an anthropomorphic thorax phantom for medical
35 imaging purposes *Med. Phys.* **45** 92–100
36
37 Hazelaar C, Verbakel W F A R, Mostafavi H, Weide L Van Der, Slotman B J, Hon F and Dahele M
38 2018c First experience with markerless on-line 3D spine position monitoring during SBRT
39 delivery using a conventional LINAC *Int. J. Radiat. Oncol. • Biol. • Phys.* **101** 1253–8
40
41 Hazelaar C, van der Weide L, Mostafavi H, Slotman B J, Verbakel W F A R and Dahele M 2018d
42 Feasibility of markerless 3D position monitoring of the central airways using kilovoltage
43 projection images: Managing the risks of central lung stereotactic radiotherapy *Radiother.*
44 *Oncol.* **129** 234–41
45
46 He P, Li Q, Liu X, Dai Z, Zhao T, Fu T, Shen G, Ma Y, Huang Q and Yan Y 2014 Respiratory
47 motion management using audio-visual biofeedback for respiratory-gated radiotherapy of
48 synchrotron-based pulsed heavy-ion beam delivery *Med. Phys.* **41** 1–11
49
50 Henke L, Kashani R, Robinson C, Curcuru A, DeWees T, Bradley J, Green O, Michalski J, Mutic S,
51 Parikh P and Olsen J 2018 Phase I trial of stereotactic MR-guided online adaptive radiation
52 therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of
53 the abdomen *Radiother. Oncol.* **126** 519–26
54
55 van Herk M 2004 Errors and margins in radiotherapy. *Semin. Radiat. Oncol.* **14** 52–64
56
57 Herschtal A, Foroudi F, Silva L, Gill S and Kron T 2013 Calculating geometrical margins for
58 hypofractionated radiotherapy *Phys. Med. Biol.* **58** 319–33
59
60 Hoisak J D P and Pawlicki T 2018 The Role of Optical Surface Imaging Systems in Radiation
Therapy *Semin. Radiat. Oncol.* **28** 185–93
61
62 Hoisak J D P, Sixel K E, Tirona R, Cheung P C F and Pignol J P 2004 Correlation of lung tumor
63 motion with external surrogate indicators of respiration *Int. J. Radiat. Oncol. Biol. Phys.* **60**

1298–306

Hoogeman M, Prévost J B, Nuyttens J, Pöll J, Levendag P and Heijmen B 2009 Clinical Accuracy of the Respiratory Tumor Tracking System of the CyberKnife: Assessment by Analysis of Log Files *Int. J. Radiat. Oncol. Biol. Phys.* **74** 297–303

Huang C-Y, Tehrani J N, Ng J A, Booth J and Keall P 2015 Six Degrees-of-Freedom Prostate and Lung Tumor Motion Measurements Using Kilovoltage Intrafraction Monitoring *Int. J. Radiat. Oncol. Biol. Phys.* **91** 368–75

Hunt M A, Sonnick M, Pham H, Regmi R, Xiong J P, Morf D, Mageras G S, Zelefsky M and Zhang P 2016 Simultaneous MV-kV imaging for intrafractional motion management during volumetric-modulated arc therapy delivery *J. Appl. Clin. Med. Phys.* **17** 473–86

Ipsen S, Bruder R, O'Brien R, Keall P J, Schweikard A and Poulsen P R 2016 Online 4D ultrasound guidance for real-time motion compensation by MLC tracking *Med. Phys.* **43** 5695–704

Ipsen S, Bruder R, Worm E S, Hansen R, Poulsen P R, Høyer M and Schweikard A 2017 Simultaneous acquisition of 4D ultrasound and wireless electromagnetic tracking for in-vivo accuracy validation *Curr. Dir. Biomed. Eng.* **3** 75–8

ISO 1994 ISO 5725-1 Accuracy (trueness and precision) of measurements methods and results

Jaffray D A 2012 Image-guided radiotherapy: From current concept to future perspectives *Nat. Rev. Clin. Oncol.* **9** 688–99

James J, Cetnar A, Dunlap N E, Huffaker C, Nguyen V N, Potts M and Wang B 2016 Validation and implementation of a wireless transponder tracking system for gated stereotactic ablative radiotherapy of the liver *Med. Phys.* **43** 2794–801

Jin J Y, Yin F F, Tenn S E, Medin P M and Solberg T D 2008 Use of the BrainLAB ExacTrac X-Ray 6D System in Image-Guided Radiotherapy *Med. Dosim.* **33** 124–34

Jones B L, Schefter T and Miften M 2015 Adaptive motion mapping in pancreatic SBRT patients using Fourier transforms *Radiother. Oncol.* **115** 217–22

Kalman R E 1960 A New Approach to Linear Filtering and Prediction Problems *J. Basic Eng.* **82** 35

Kamerling C P, Fast M F, Ziegenhein P, Menten M J, Nill S and Oelfke U 2017 Online dose reconstruction for tracked volumetric arc therapy: Real-time implementation and offline quality assurance for prostate SBRT *Med. Phys.* **44** 5997–007

Kamerling C P, Fast M F, Ziegenhein P, Menten M J, Nill S and Oelfke U 2016a Real-time 4D dose reconstruction for tracked dynamic MLC deliveries for lung SBRT *Med. Phys.* **43** 6072–81

Kamerling C P, Fast M F, Ziegenhein P, Nill S and Oelfke U 2016b TH-CD-202-12: Online Inter-Beam Replanning Based On Real-Time Dose Reconstruction *Med. Phys.* **43**

Kamino Y, Takayama K, Kokubo M, Narita Y, Hirai E, Kawawda N, Mizowaki T, Nagata Y, Nishidai T and Hiraoka M 2006 Development of a four-dimensional image-guided radiotherapy system with a gimballed X-ray head *Int. J. Radiat. Oncol. Biol. Phys.* **66** 271–8

Kashani R, Lam K, Litzenberg D and Balter J 2007 Technical note: A deformable phantom for dynamic modeling in radiation therapy *Med. Phys.* **34** 199–201

Keall P J, Aun Ng J, O'Brien R, Colvill E, Huang C-Y, Rugaard Poulsen P, Fledelius W, Juneja P, Simpson E, Bell L, Alfieri F, Eade T, Kneebone A and Booth J T 2015 The first clinical treatment with kilovoltage intrafraction monitoring (KIM): A real-time image guidance method *Med. Phys.* **42** 354–8

Keall P J, Barton M and Crozier S 2014a The Australian Magnetic Resonance Imaging-Linac Program *Semin. Radiat. Oncol.* **24** 203–6

Keall P J, Colvill E, O'Brien R, Ng J A, Poulsen P R, Eade T, Kneebone A and Booth J T 2014b The first clinical implementation of electromagnetic transponder-guided MLC tracking. *Med. Phys.*

1
2
3 41 020702
4
5

6 Keall P J, Mageras G S, Balter J M, Emery R S, Forster K M, Jiang S B, Kapatoes J M, Low D A,
7 Murphy M J, Murray B R, Ramsey C R, Van Herk M B, Vedam S S, Wong J W and Yorke E
8 2006 The management of respiratory motion in radiation oncology report of AAPM Task Group
9 76. *Med. Phys.* **33** 3874–900

10 Keall P J, Ng J A, Juneja P, O'Brien R T, Huang C-Y, Colvill E, Caillet V, Simpson E, Poulsen P R,
11 Kneebone A, Eade T and Booth J T 2016 Real-Time 3D Image Guidance Using a Standard
12 LINAC : Measured Motion , Accuracy , and Precision of the First Prospective Clinical Trial of
13 Kilovoltage Intrafraction Monitoring-Guided Gating for Prostate Cancer Radiation Therapy
14 *Radiat. Oncol. Biol.* **94** 1015–21

15 Keall P J, Nguyen D T, O'Brien R, Caillet V, Hewson E, Poulsen P R, Bromley R, Bell L, Eade T,
16 Kneebone A, Martin J and Booth J T 2018a The first clinical implementation of real-time image-
17 guided adaptive radiotherapy using a standard linear accelerator *Radiother. Oncol.* **127** 6–11

18 Keall P J, Nguyen D T, O'Brien R, Zhang P, Happerset L, Bertholet J and Poulsen P R 2018b
19 Review of Real-Time 3-Dimensional Image Guided Radiation Therapy on Standard-Equipped
20 Cancer Radiation Therapy Systems: Are We at the Tipping Point for the Era of Real-Time
21 Radiation Therapy? *Int. J. Radiat. Oncol.* **102** 922–31

22 Kim J H, Nguyen D T, Huang C Y, Fuangrod T, Caillet V, O'Brien R, Poulsen P, Booth J and Keall P
23 2017 Quantifying the accuracy and precision of a novel real-time 6 degree-of-freedom
24 kilovoltage intrafraction monitoring (KIM) target tracking system *Phys. Med. Biol.* **62** 5744–59

25 Kindblom J, Ekelund-Olvenmark A M, Syren H, Iustin R, Braide K, Frank-Lissbrant I and Lennernäs
26 B 2009 High precision transponder localization using a novel electromagnetic positioning
27 system in patients with localized prostate cancer *Radiother. Oncol.* **90** 307–11

28 King C R, Brooks J D, Gill H and Presti J C 2012 Long-Term Outcomes From a Prospective Trial of
29 Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer *Int. J. Radiat. Oncol. Biol. Phys.*
30 **82** 877–82

31 Kinoshita R, Shimizu S, Taguchi H, Katoh N, Fujino M, Onimaru R, Aoyama H, Katoh F, Omatsu T,
32 Ishikawa M and Shirato H 2008 Three-Dimensional Intrafractional Motion of Breast During
33 Tangential Breast Irradiation Monitored With High-Sampling Frequency Using a Real-Time
34 Tumor-Tracking Radiotherapy System *Int. J. Radiat. Oncol. Biol. Phys.* **70** 931–4

35 Kitamura K, Shirato H, Seppenwoolde Y, Shimizu T, Kodama Y, Endo H, Onimaru R, Oda M, Fujita
36 K, Shimizu S and Miyasaka K 2003 Tumor location, cirrhosis, and surgical history contribute to
37 tumor movement in the liver, as measured during stereotactic irradiation using a real-time
38 tumor-tracking radiotherapy system *Int. J. Radiat. Oncol. Biol. Phys.* **56** 221–8

39 Kitamura K, Shirato H, Shimizu S, Shinohara N, Harabayashi T, Shimizu T, Kodama Y, Endo H,
40 Onimaru R, Nishioka S, Aoyama H, Tsuchiya K and Miyasaka K 2002 Registration accuracy
41 and possible migration of internal fiducial gold marker implanted in prostate and liver treated
42 with real-time tumor-tracking radiation therapy (RTTRT) *Radiother. Oncol.* **62** 275–81

43 Klein E E, Hanley J, Bayouth J, Yin F-F, Simon W, Dresser S, Serago C, Aguirre F, Ma L,
44 Arjomandy B, Liu C, Sandin C and Holmes T 2009 Task Group 142 report: Quality assurance of
45 medical accelerators *Med. Phys.* **36** 4197–212

46 Klimpki G, Zhang Y, Fattori G, Psoroulas S, Weber D C, Lomax A and Meer D 2018 The impact of
47 pencil beam scanning techniques on the effectiveness and efficiency of rescanning moving
48 targets *Phys. Med. Biol.* **63**

49 Knopf A C, Stützer K, Richter C, Rucinski A, da Silva J, Phillips J, Engelsman M, Shimizu S, Werner
50 R, Jakobi A, Göksel O, Zhang Y, Oshea T, Fast M, Perrin R, Bert C, Rinaldi I, Korevaar E K
51 and McClelland J 2016 Required transition from research to clinical application: Report on the
52 4D treatment planning workshops 2014 and 2015 *Phys. Medica* **32** 874–82

1
2
3 Kontaxis C, Bol G H, Stemkens B, Glitzner M, Prins F M, Kerkmeijer L G W, Lagendijk J J W and
4 Raaymakers B W 2017 Towards fast online intrafraction replanning for free-breathing
5 stereotactic body radiation therapy with the MR-linac *Phys. Med. Biol.* **62** 7233–48
6
7 Kothary N, Heit J J, Louie J D, Kuo W T, Loo B W, Koong A, Chang D T, Hovsepian D, Sze D Y
8 and Hofmann L V. 2009 Safety and Efficacy of Percutaneous Fiducial Marker Implantation for
9 Image-guided Radiation Therapy *J. Vasc. Interv. Radiol.* **20** 235–9
10
11 Krieger M, Klimpki G, Fattori G, Hrbacek J, Oxley D, Safai S, Weber D C, Lomax A J and Zhang Y
12 2018 Experimental validation of a deforming grid 4D dose calculation for PBS proton therapy
13 *Phys. Med. Biol.* **63**
14
15 De Kruijf W J M, Verstraete J, Neustadter D, Corn B W, Hol S, Venselaar J L M, Davits R J,
16 Wijsman B P, Van Den Bergh L, Budiharto T, Oyen R, Haustermans K and Poortmans P M P
17 2013 Patient positioning based on a radioactive tracer implanted in patients with localized
18 prostate cancer: A performance and safety evaluation *Int. J. Radiat. Oncol. Biol. Phys.* **85** 555–
19 60
20
21 Kubiak T 2016 Particle therapy of moving targets-the strategies for tumour motion monitoring and
22 moving targets irradiation *Br. J. Radiol.* **89**
23
24 Kubo H D and Hill B C 1996 Physics in Medicine & Biology Respiration gated radiotherapy
25 treatment: a technical study *Phys. Med. Biol.* **41** 83–91
26
27 Kupelian P, Willoughby T, Mahadevan A, Djemil T, Weinstein G, Jani S, Enke C, Solberg T, Flores
28 N, Liu D, Beyer D and Levine L 2007 Multi-institutional clinical experience with the Calypso
29 System in localization and continuous, real-time monitoring of the prostate gland during external
radiotherapy. *Int. J. Radiat. Oncol. Biol. Phys.* **67** 1088–98
30
31 Kyriakou E and McKenzie D R 2012 Changes in lung tumor shape during respiration *Phys. Med.*
32 *Biol.* **57** 919–35
33
34 Lachaine M and Falco T 2013 Intrafractional prostate motion management with the clarity autoscan
35 system *Med. Phys. Int.* **53** 1689–99
36
37 Lagendijk J J W, Raaymakers B W and van Vulpen M 2014 The Magnetic Resonance Imaging-Linac
38 System *Semin. Radiat. Oncol.* **24** 207–9
39
40 Landry G and Hua C 2018 Current state and future applications of radiological image guidance for
41 particle therapy *Med. Phys.* **45** e1086–95
42
43 Langen K M, Willoughby T R, Meeks S L, Santhanam A, Cunningham A, Levine L and Kupelian P
44 A 2008 Observations on real-time prostate gland motion using electromagnetic tracking. *Int. J.*
45 *Radiat. Oncol. Biol. Phys.* **71** 1084–90
46
47 Lewis J H, Li R, Watkins W T, Lawson J D, Segars W P, Cerviño L I, Song W Y and Jiang S B 2010
48 Markerless lung tumor tracking and trajectory reconstruction using rotational cone-beam
49 projections: A feasibility study *Phys. Med. Biol.* **55** 2505–22
50
51 Li G, Ballangrud Å, Kuo L C, Kang H, Kirov A, Lovelock M, Yamada Y, Mechalekos J and Amols H
52 2011a Motion monitoring for cranial frameless stereotactic radiosurgery using video-based
53 three-dimensional optical surface imaging *Med. Phys.* **38** 3981–94
54
55 Li M, Hegemann N-S, Manapov F, Kolberg A, Thum P D, Ganswindt U, Belka C and Ballhausen H
56 2017 Prefraction displacement and intrafraction drift of the prostate due to perineal ultrasound
57 probe pressure *Strahlentherapie und Onkol.* **193** 459–65
58
59 Li R, Fahimian B P and Xing L 2011b A Bayesian approach to real-time 3D tumor localization via
60 monoscopic x-ray imaging during treatment delivery *Med. Phys.* **38** 4205–14
61
62 Li R, Mok E, Han B, Koong A and Xing L 2012 Evaluation of the geometric accuracy of surrogate-
63 based gated VMAT using intrafraction kilovoltage x-ray images *Med. Phys.* **39** 2686
64
65 Lightstone A W, Benedict S H, Bova F J, Solberg T D and Stern R L 2005 Intracranial stereotactic

1
2
3 positioning systems: Report of the American Association of Physicists in Medicine Radiation
4 Therapy Committee Task Group No. 68 *Med. Phys.* **32** 2380–98
5
6 Lin W-Y, Lin S-F, Yang S-C, Liou S-C, Nath R and Liu W 2013 Real-time automatic fiducial marker
7 tracking in low contrast cine-MV images *Med. Phys.* **40** 011715
8
9 Liney G P, Dong B, Begg J, Vial P, Zhang K, Lee F, Walker A, Rai R, Causer T, Alnaghy S J, Oborn
10 B M, Holloway L, Metcalfe P, Barton M, Crozier S and Keall P 2016 Technical Note:
11 Experimental results from a prototype high-field inline MRI-linac *Med. Phys.* **43** 5188–94
12
13 De Los Santos J, Popple R, Agazaryan N, Bayouth J E, Bissonnette J P, Bucci M K, Dieterich S,
14 Dong L, Forster K M, Indelicato D, Langen K, Lehmann J, Mayr N, Parsai I, Salter W, Tomblyn
15 M, Yuh W T C and Chetty I J 2013 Image guided radiation therapy (IGRT) technologies for
16 radiation therapy localization and delivery *Int. J. Radiat. Oncol. Biol. Phys.* **87** 33–45
17
18 De Luca V, Banerjee J, Hallack A, Kondo S, Makhinya M, Nouri D, Royer L, Cifor A, Dardenne G,
19 Goksel O, Gooding M J, Klink C, Krupa A, Le Bras A, Marchal M, Moelker A, Niessen W J,
20 Papiez B W, Rothberg A, Schnabel J, van Walsum T, Harris E, Lediju Bell M A and Tanner C
21 2018 Evaluation of 2D and 3D ultrasound tracking algorithms and impact on ultrasound-guided
22 liver radiotherapy margins *Med. Phys.* **45** 4986–5003
23
24 Luo W, Yoo S, Wu Q J, Wang Z and Yin F F 2008 Analysis of image quality for real-time target
25 tracking using simultaneous kV-MV imaging *Med. Phys.* **35** 5501–9
26
27 Ma Z, Zhang W, Su Y, Liu P, Pan Y, Zhang G and Song Y 2018 Optical Surface Management
28 System for Patient Positioning in Interfractional Breast Cancer Radiotherapy *Biomed Res. Int.*
29 **2018** 1–8
30
31 Malinowski K, McAvoy T J, George R, Dieterich S and D’Souza W D 2013 Maintaining tumor
32 targeting accuracy in real-time motion compensation systems for respiration-induced tumor
33 motion *Med. Phys.* **40** 071709
34
35 Malinowski K, McAvoy T J, George R, Dietrich S and D’Souza W D 2012 Incidence of changes in
36 respiration-induced tumor motion and its relationship with respiratory surrogates during
37 individual treatment fractions *Int. J. Radiat. Oncol. Biol. Phys.* **82** 1665–73
38
39 Malinowski K, Noel C, Lu W, Lechleiter K, Hubenschmidt J, Low D and Parikh P 2007 Development
40 of the 4D Phantom for patient-specific, end-to-end radiation therapy QA Proc. *SPIE* **6510**
41 65100E–65100E–9
42
43 Mao W, Wiersma R D and Xing L 2008 Fast internal marker tracking algorithm for onboard MV and
44 kV imaging systems *Med. Phys.* **35** 1942–9
45
46 Marchant T E, Skalski A and Matuszewski B J 2012 Automatic tracking of implanted fiducial
47 markers in cone beam CT projection images *Med. Phys.* **39** 1322
48
49 Martin J, McClelland J, Yip C, Thomas C, Hartill C, Ahmad S, Meir I, Landau D and Hawkes D 2014
50 Fully-deformable patient motion models from cone-beam CT for radiotherapy applications
51 *Journal of Physics: Conference Series* vol 489
52
53 Mazur T R, Fischer-Valuck B W, Wang Y, Yang D, Mutic S and Li H H 2015 SIFT-based dense
54 pixel tracking on 0.35 T cine-MR images acquired during image-guided radiation therapy with
55 application to gating optimization *Med. Phys.* **43** 279–93
56
57 McClelland J R, Hawkes D J, Schaeffter T and King A P 2013 Respiratory motion models: A review
58 *Med. Image Anal.* **17**
59
60 McClelland J R, Modat M, Arridge S, Grimes H, Souza D D, Thomas D, Connell D O, Low D A,
Kaza E, Collins D J, Leach M O and Hawkes D J 2017 A generalized framework unifying image
registration and respiratory motion models and incorporating image reconstruction, for partial or
full imaging data *Phys. Med. Biol.* **62** 4273–92 Online: <https://doi.org/10.1088/1361-6560/aa6070>

1
2
3 McNair H A, Brock J, Symonds-Tayler J R N, Ashley S, Eagle S, Evans P M, Kavanagh A, Panakis
4 N and Brada M 2009 Feasibility of the use of the Active Breathing Co ordinatorTM (ABC) in
5 patients receiving radical radiotherapy for non-small cell lung cancer (NSCLC) *Radiother.*
6 *Oncol.* **93** 424–9

7 Meijers A, Jakobi A, Stützer K, Gutteres Marmitt G, Both S, Langendijk J, Richter C and Knopf A
8 2019 Log file based dose reconstruction and accumulation for 4D adaptive pencil beam scanned
9 proton therapy in a clinical treatment planning system: Implementation and proof-of-concept
10 *Med. Phys.*

11 Menten M J, Fast M F, Wetscherek A, Rank C M, Kachelrieß M, Collins D J, Nill S and Oelfke U
12 2018 The impact of 2D cine MR imaging parameters on automated tumor and organ localization
13 for MR-guided real-time adaptive radiotherapy *Phys. Med. Biol.* **63** 235005

14 Menten M J, Guckenberger M, Herrmann C, Krauß A, Nill S, Oelfke U and Wilbert J 2012
15 Comparison of a multileaf collimator tracking system and a robotic treatment couch tracking
16 system for organ motion compensation during radiotherapy *Med. Phys.* **39** 7032–41

17 Meschini G, Seregni M, Pella A, Ciocca M, Fossati P, Valvo F, Riboldi M and Baroni G 2017
18 Evaluation of residual abdominal tumour motion in carbon ion gated treatments through
19 respiratory motion modelling *Phys. Medica* **34** 28–37

20 Minohara S, Kanai T, Masahiro E, Noda K and Kanazawa M 2000 Respiratory gated irradiation
21 system for heavy-ion radiotherapy ed Intergovernmental Panel on Climate Change *Int. J. Radiat.*
22 *Oncol. Biol. Phys.* **47** 1097–103

23 Mishra P, St. James S, Segars W P, Berbeco R I and Lewis J H 2012 Adaptation and applications of a
24 realistic digital phantom based on patient lung tumor trajectories *Phys. Med. Biol.* **57** 3597–608

25 Molloy J A, Chan G, Markovic A, McNeeley S, Pfeiffer D, Salter B and Tome W A 2011 Quality
26 assurance of U.S.-guided external beam radiotherapy for prostate cancer: Report of AAPM Task
27 Group 154 *Med. Phys.* **38** 857–71

28 Montanaro T, Nguyen D T, Keall P J, Booth J, Caillet V, Eade T, Haddad C and Shieh C C 2018 A
29 comparison of gantry-mounted x-ray-based real-time target tracking methods: *Med. Phys.* **45**
30 1222–32

31 Mori S, Karube M, Shirai T, Tajiri M, Takekoshi T, Miki K, Shiraishi Y, Tanimoto K, Shibayama K,
32 Yasuda S, Yamamoto N, Yamada S, Tsuji H, Noda K and Kamada T 2016 Carbon-Ion Pencil
33 Beam Scanning Treatment with Gated Markerless Tumor Tracking: An Analysis of Positional
34 Accuracy *Int. J. Radiat. Oncol. Biol. Phys.* **95** 258–66

35 Mostafaei F, Tai A, Gore E, Johnstone C, Haase W, Ehlers C, Cooper D T, Lachaine M and Li X A
36 2018 Feasibility of real-time lung tumor motion monitoring using intrafractional ultrasound and
37 kV cone beam projection images *Med. Phys.* **45** 4619–26

38 Moteabbed M, Schuemann J and Paganetti H 2014 Dosimetric feasibility of real-time MRI-guided
39 proton therapy *Med. Phys.* **41**

40 Murphy M J, Adler J R, Bodduluri M, Dooley J, Forster K, Hai J, Le Q, Luxton G, Martin D and Poen
41 J 2000 Image-guided radiosurgery for the spine and pancreas *Comput. Aided Surg.* **5** 278–88

42 Murphy M J, Balter J, Balter S, Bencomo J A, Das I J, Jiang S B, Ma C M, Olivera G H, Rodebaugh
43 R F, Ruchala K J, Shirato H and Yin F F 2007 The management of imaging dose during image-
44 guided radiotherapy: Report of the AAPM Task Group 75 *Med. Phys.* **34** 4041–63

45 Mutic S and Dempsey J F 2014 The ViewRay System: Magnetic Resonance-Guided and Controlled
46 Radiotherapy *Semin. Radiat. Oncol.* **24** 196–9

47 Mutic S, Low D, Chmielewski T, Fought G, Gerganov G, Hernandez M, Kawrakow I, Kishawi E,
48 Kuduvali G, Sharma A, Shvartsman S, Tabachnik J, Kashani R, Green O L and Dempsey J F
49 2016 The Design and Implementation of a Novel Compact Linear Accelerator-Based Magnetic
50 Resonance Imaging–Guided Radiation Therapy (MR-IGRT) System *Int. J. Radiat. Oncol.* **96**

1
2
3 E641
4
5

Nankali S, Worm E S, Hansen R, Weber B, Høyer M, Zirak A and Poulsen P R 2018 Geometric and dosimetric comparison of four intrafraction motion adaptation strategies for stereotactic liver radiotherapy *Phys. Med. Biol.* **63** 12pp

National Library of Medicine Visible Human Male and Female datasets, http://www.nlm.nih.gov/research/visible/visible_human.html

Ng J A, Booth J, Poulsen P, Kuncic Z and Keall P J 2013 Estimation of effective imaging dose for kilovoltage intratreatment monitoring of the prostate position during cancer radiotherapy *Phys. Med. Biol.* **58** 5983–96

Ng J A, Booth J T, O'Brien R T, Colvill E, Huang C-Y, Poulsen P R and Keall P J 2014 Quality assurance for the clinical implementation of kilovoltage intrafraction monitoring for prostate cancer VMAT. *Med. Phys.* **41** 111712

Ng J A, Booth J T, Poulsen P R, Fledelius W, Worm E S, Eade T, Hegi F, Kneebone A, Kuncic Z and Keall P J 2012 Kilovoltage intrafraction monitoring for prostate intensity modulated arc therapy: first clinical results. *Int. J. Radiat. Oncol. Biol. Phys.* **84** e655-61

Nguyen D T, Bertholet J, Kim J, O'Brien R, Booth J T, Poulsen P R and Keall P J 2017a An interdimensional correlation framework for real-time estimation of six degree of freedom target motion using a single x-ray imager during radiotherapy *Phys. Med. Biol.* **63** 015010

Nguyen D T, Booth J T, Caillet V, Hardcastle N, Briggs A, Haddad C, Eade T, O'Brien R and Keall P J 2018 An augmented correlation framework for the estimation of tumour translational and rotational motion during external beam radiotherapy treatments using intermittent monoscopic X-ray imaging and an external respiratory signal *Phys. Med. Biol.* **63** 205003(17pp)

Nguyen D T, O'Brien R, Kim J H, Huang C Y, Wilton L, Greer P, Legge K, Booth J T, Poulsen P R, Martin J and Keall P J 2017b The first clinical implementation of a real-time six degree of freedom target tracking system during radiation therapy based on Kilovoltage Intrafraction Monitoring (KIM) *Radiother. Oncol.* **123** 37–42

Nioutsikou E, Richard N Symonds-Tayler J, Bedford J L and Webb S 2006 Quantifying the effect of respiratory motion on lung tumour dosimetry with the aid of a breathing phantom with deforming lungs *Phys. Med. Biol.* **51** 3359–74

Oborn B M, Dowdell S, Metcalfe P E, Crozier S, Mohan R and Keall P J 2015 Proton beam deflection in MRI fields: Implications for MRI-guided proton therapy *Med. Phys.* **42** 2113–24

Oborn B M, Dowdell S, Metcalfe P E, Crozier S, Mohan R, Keall P J, Cancer S, Centre C and Engineering E 2017 Future of Medical Physics: Real-time MRI guided Proton Therapy *Med. Phys.* **44** e77–90

Omari E A, Erickson B, Ehlers C, Quiroz F, Noid G, Cooper D T, Lachaine M and Li X A 2016 Preliminary results on the feasibility of using ultrasound to monitor intrafractional motion during radiation therapy for pancreatic cancer *Med. Phys.* **43** 5252–60

Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K and Araki T 2007 Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study *J. Thorac. Oncol.* **2** S94–100

Ozhasoglu C, Saw C B, Chen H, Burton S, Komanduri K, Yue N J, Huq S M and Heron D E 2008 Synchrony - Cyberknife Respiratory Compensation Technology *Med. Dosim.* **33** 117–23

Paganelli C, Lee D, Greer P B, Baroni G, Riboldi M and Keall P 2015 Quantification of lung tumor rotation with automated landmark extraction using orthogonal cine MRI images *Phys. Med. Biol.* **60** 7165–78

1
2
3 Paganelli C, Summers P, Gianoli C, Bellomi M, Baroni G and Riboldi M 2017 A tool for validating
4 MRI-guided strategies: a digital breathing CT/MRI phantom of the abdominal site *Med. Biol.*
5 *Eng. Comput.* **55** 2001–14
6
7 Paganelli C, Whelan B M, Peroni M, Summers P, Fast M F, van de Lindt T, McClelland J R, Eiben B,
8 Keall P J, Lomax A J, Riboldi M and Baroni G 2018 MRI-guidance for motion management in
9 external beam radiotherapy: current status and future challenges *Phys. Med. Biol.* **25** 2025–31
10
11 Pan H, Cerviño L I, Pawlicki T, Jiang S B, Alksne J, Detorie N, Russell M, Carter B S, Murphy K T,
12 Mundt A J, Chen C and Lawson J D 2012 Frameless, Real-Time, Surface Imaging-Guided
13 Radiosurgery *Neurosurgery* **71** 844–52
14
15 Park J C, Park S H, Kim J H, Yoon S M, Song S Y, Liu Z, Song B, Kauweloa K, Webster M J,
16 Sandhu A, Mell L K, Jiang S B, Mundt A J and Song W Y 2012 Liver motion during cone beam
17 computed tomography guided stereotactic body radiation therapy *Med. Phys.* **39** 6431
18
19 Patel R, Panfil J, Campana M, Block A M, Harkenrider M M, Surucu M and Roeske J C 2015
20 Markerless motion tracking of lung tumors using dual-energy fluoroscopy *Med. Phys.* **42** 254–
62
21
22 Pedroni E 2006 System for taking wide-field beam-eye-view (BEV) x-ray-images simultaneously to
23 the proton therapy delivery World Intellectual Property Organization Patent WO 2006/094533/A1
24
25 Perrin R L, Zakova M, Peroni M, Bernatowicz K, Bikis C, Knopf A K, Safai S, Fernandez-Carmona
26 P, Tscharner N, Weber D C, Parkel T C and Lomax A J 2017 An anthropomorphic breathing
27 phantom of the thorax for testing new motion mitigation techniques for pencil beam scanning
28 proton therapy *Phys. Med. Biol.* **62** 2486–504
29
30 Pfeiler T, Bäumer C, Engwall E, Geismar D, Spaan B and Timmermann B 2018 Experimental
31 validation of a 4D dose calculation routine for pencil beam scanning proton therapy *Z. Med.*
32 *Phys.* **28** 121–33
33
34 Poels K, Depuydt T, Verellen D, Gevaert T, Dhont J, Duchateau M, Burghelea M, Boussaer M,
35 Steenbeke F, Collen C, Engels B, Storme G and De Ridder M 2014 Improving the intra-fraction
36 update efficiency of a correlation model used for internal motion estimation during real-time
37 tumor tracking for SBRT patients: Fast update or no update? *Radiother. Oncol.* **112** 352–9
38
39 Poels K, Dhont J, Verellen D, Blanck O, Ernst F, Vandemeulebroucke J, Depuydt T, Storme G and
40 De Ridder M 2015 A comparison of two clinical correlation models used for real-time tumor
41 tracking of semi-periodic motion: A focus on geometrical accuracy in lung and liver cancer
42 patients *Radiother. Oncol.* **115** 419–24
43
44 Poulsen P R, Carl J, Nielsen J, Nielsen M S, Thomsen J B, Jensen H K, Kjærgaard B, Zepernick P R,
45 Worm E, Fledelius W, Cho B, Sawant A, Ruan D and Keall P J 2012a Megavoltage image-
46 based dynamic multileaf collimator tracking of a NiTi stent in porcine lungs on a linear
47 accelerator *Int. J. Radiat. Oncol. Biol. Phys.* **82** 321–7
48
49 Poulsen P R, Cho B and Keall P J 2008a A Method to Estimate Mean Position, Motion Magnitude,
50 Motion Correlation, and Trajectory of a Tumor From Cone-Beam CT Projections for Image-
51 Guided Radiotherapy *Int. J. Radiat. Oncol. Biol. Phys.* **72** 1587–96
52
53 Poulsen P R, Cho B, Langen K, Kupelian P and Keall P J 2008b Three-dimensional prostate position
54 estimation with a single x-ray imager utilizing the spatial probability density. *Phys. Med. Biol.*
55 **53** 4331–53
56
57 Poulsen P R, Jonassen J, Schmidt M L and Jensen C 2015a Improved quality of intrafraction
58 kilovoltage images by triggered readout of unexposed frames *Med. Phys.* **42** 6549–57
59
60 Poulsen P R, Worm E S, Hansen R, Larsen L P, Grau C and Høyer M 2015b Respiratory gating based
on internal electromagnetic motion monitoring during stereotactic liver radiation therapy: First
results *Acta Oncol. (Madr.)* **54** 1445–52
Poulsen P R, Worm E S, Petersen J B B, Grau C, Fledelius W and Høyer M 2014 Kilovoltage

1 intrafraction motion monitoring and target dose reconstruction for stereotactic volumetric
2 modulated arc therapy of tumors in the liver *Radiother. Oncol.* **111** 424–30

3 Poulsen P, Schmidt M, Keall P, Worm E, Fledelius W and Hoffmann L 2012b A method of dose
4 reconstruction for moving targets compatible with dynamic treatments *Med. Phys.* **39** 6237–46

5 Prall M, Kaderka R, Saito N, Graeff C, Bert C, Durante M, Parodi K, Schwaab J, Sarti C and Jenne J
6 2014 Ion beam tracking using ultrasound motion detection *Med. Phys.* **41**

7 Prévost J G, Hoogeman M S, Pöll J J, Dijk L C Van and Pattynama P M T 2008 Endovascular coils as
8 lung tumour markers in real-time tumour tracking stereotactic radiotherapy : preliminary results
9 1569–76

10 Raaymakers B W, Jürgenliemk-Schulz I M, Bol G H, Glitzner M, Kotte A N T J, Asselen B van, de
11 Boer J C J, Bluemink J J, Hackett S L, Moerland M A, Woodings S J, Wolthaus J W H, Zijp H
12 M van, Philippens M E P, Tijssen R, Kok J G M, Breugel E N de G, Kiekebosch I, Meijers L T
13 C, Nomden C N, Sikkes G G, Doornaert P A H, Eppinga W S C, Kasperts N, Kerkmeijer L G
14 W, Tersteeg J H A, Brown K J, Pais B, Woodhead P and Lagendijk J J W 2017 First patients
15 treated with a 1.5T MRI-Linac: clinical proof of concept of a high-precision, high-field MRI
16 guided radiotherapy treatment *Phys. Med. Biol.* **62** L41–50

17 Raaymakers B W, Lagendijk J J W, Overweg J, Kok J G M, Raaijmakers A J E, Kerkhof E M, van
18 der Put R W, Meijising I, Crijns S P M, Benedosso F, van Vulpen M, de Graaff C H W, Allen J
19 and Brown K J 2009 Integrating a 1.5 T MRI scanner with a 6 MV accelerator: proof of concept
20 *Phys. Med. Biol.* **54** N229–37

21 Raaymakers B W, Raaijmakers A and Lagendijk J 2008 SU-GG-T-376: Feasibility of MRI Guided
22 Proton Therapy: Magnetic Field Dose Effects *Med. Phys.* **35** 2811–2

23 Ravkilde T, Keall P J, Grau C, Høyer M and Poulsen P R 2014 Fast motion-including dose error
24 reconstruction for VMAT with and without MLC tracking. *Phys. Med. Biol.* **59** 7279–96

25 Ravkilde T, Skouboe S, Hansen R, Worm E and Poulsen P R 2018 First online real-time evaluation of
26 motion-induced 4D dose errors during radiotherapy delivery *Med. Phys.* **45** 3893–903

27 Regmi R, Lovelock D M, Hunt M, Zhang P, Pham H, Xiong J, Yorke E D, Goodman K A, Rimmer A,
28 Mostafavi H and Mageras G S 2014 Automatic tracking of arbitrarily shaped implanted markers
29 in kilovoltage projection images: a feasibility study. *Med. Phys.* **41** 071906

30 Remmert G, Biederer J, Lohberger F, Fabel M and Hartmann G H 2007 Four-dimensional magnetic
31 resonance imaging for the determination of tumour movement and its evaluation using a
32 dynamic porcine lung phantom *Phys. Med. Biol.* **52** N401–15

33 Remouchamps V M, Letts N, Yan D, Vicini F A, Moreau M, Zielinski J A, Liang J, Kestin L L,
34 Martinez A A and Wong J W 2003 Three-dimensional evaluation of intra- and interfraction
35 immobilization of lung and chest wall using active breathing control: A reproducibility study
36 with breast cancer patients *Int. J. Radiat. Oncol. Biol. Phys.* **57** 968–78

37 Ren L, Zhang Y and Yin F F 2014 A limited-angle intrafraction verification (LIVE) system for
38 radiation therapy *Med. Phys.* **41**

39 Riboldi M, Orecchia R and Baroni G 2012 Real-time tumour tracking in particle therapy:
40 Technological developments and future perspectives *Lancet Oncol.* **13** e383–91

41 Richter A, Wilbert J, Baier K, Flentje M and Guckenberger M 2010 Feasibility study for markerless
42 tracking of lung tumors in stereotactic body radiotherapy *Int. J. Radiat. Oncol. Biol. Phys.* **78**
43 618–27

44 Ronneberger O, Fischer P and Brox T 2015 U-net: Convolutional networks for biomedical image
45 segmentation *Lect. Notes Comput. Sci. (including Subser. Lect. Notes Artif. Intell. Lect. Notes
46 Bioinformatics)* **9351** 234–41

47 Rose M, Siva S, Ball D, Irving L B and Steinfort D P 2014 Bronchoscopic delivery of lipiodol as a
48

1 fiducial marker in lung tumors before radiotherapy *J. Thorac. Oncol.* **9** 1579–83

2 Rottmann J, Keall P and Berbeco R 2013 Markerless EPID image guided dynamic multi-leaf

3 collimator tracking for lung tumors *Phys. Med. Biol.* **58** 4195–204

4 Ruan D, Fessler J A, Balter J M, Berbeco R I, Nishioka S and Shirato H 2008 Inference of hysteretic

5 respiratory tumor motion from external surrogates: a state augmentation approach. *Phys. Med.*

6 *Biol.* **53** 2923–36

7 De Ruysscher D, Sterpin E, Haustermans K and Depuydt T 2015 Tumour movement in proton

8 therapy: Solutions and remaining questions: A review *Cancers (Basel)*. **7** 1143–53

9 Safai S, Bula C, Meer D and Pedroni E 2012 Improving the precision and performance of proton

10 pencil beam scanning *Transl. Cancer Res.* **1** 196–206

11 Santanam L, Noel C, Willoughby T R, Esthappan J, Mutic S, Klein E E, Low D A and Parikh P J

12 2009 Quality assurance for clinical implementation of an electromagnetic tracking system *Med.*

13 *Phys.* **36** 3477–86

14 Sawant A, Dieterich S, Svatos M and Keall P 2010 Failure mode and effect analysis-based quality

15 assurance for dynamic MLC tracking systems *Med. Phys.* **37** 6466–79

16 Schellhammer S M, Hoffmann A L, Gantz S, Smeets J, Kraaij E Van Der, Quets S, Pieck S, Karsch L

17 and Pawelke J 2018 Integrating a low-field open MR scanner with a static proton research beam

18 line : proof of concept *Phys. Med. Biol.* **63** 23LT01 (8pp)

19 Scherman Rydhög J, Riisgaard de Blanck S, Josipovic M, Jølck R I, Larsen K R, Clementsen P,

20 Andersen T L, Poulsen P R, Persson G F and Munck af Rosenschold P 2017 Target position

21 uncertainty during visually guided deep-inspiration breath-hold radiotherapy in locally advanced

22 lung cancer *Radiother. Oncol.* **123** 78–84

23 Schlosser J, Gong R H, Bruder R, Schweikard A, Jang S, Henrie J, Kamaya A, Koong A, Chang D T

24 and Hristov D 2016 Robotic intrafractional US guidance for liver SABR: System design, beam

25 avoidance, and clinical imaging *Med. Phys.* **43** 5951–63

26 Schlosser J and Hristov D 2016 Radiolucent 4D Ultrasound Imaging: System Design and Application

27 to Radiotherapy Guidance *IEEE Trans. Med. Imaging* **35** 2292–300

28 Schlosser J, Salisbury K and Hristov D 2012 Online image-based monitoring of soft-tissue

29 displacements for radiation therapy of the prostate *Int. J. Radiat. Oncol. Biol. Phys.* **83** 1633–40

30 Schlosser J, Salisbury K and Hristov D 2010 Telerobotic system concept for real-time soft-tissue

31 imaging during radiotherapy beam delivery *Med. Phys.* **37** 6357–67

32 Schmidt M L, Hoffmann L, Knap M M, Rasmussen T R, Folkersen B H, Toftegaard J, Møller D S

33 and Poulsen P R 2016 Cardiac and respiration induced motion of mediastinal lymph node targets

34 in lung cancer patients throughout the radiotherapy treatment course *Radiother. Oncol.* **121** 52–8

35 Schmitt D, Nill S, Roeder F, Gompelmann D, Herth F and Oelfke U 2017 Motion monitoring during a

36 course of lung radiotherapy with anchored electromagnetic transponders *Strahlentherapie und*

37 *Onkol.* **193** 840–7

38 Schnarr E, Beneke M, Casey D, Chao E, Chappelow J, Cox A, Henderson D, Jordan P, Lessard E,

39 Lucas D, Myronenko A and Maurer C 2018 Feasibility of real-time motion management with

40 helical tomotherapy *Med. Phys.* 1329–37

41 Seco J and Spadea M F 2015 Imaging in particle therapy: State of the art and future perspective *Acta*

42 *Oncol. (Madr)*. **54** 1254–8

43 Segars W P, Sturgeon G, Mendonca S, Grimes J and Tsui B M W 2010 4D XCAT phantom for

44 multimodality imaging research *Med. Phys.* **37** 4902–15

45 Seiler P G, Blattmann H, Kirsch S, Muench R K and Schilling C 2000 A novel tracking technique for

46 the continuous precise measurement of tumour positions in conformal radiotherapy *Phys. Med.*

47

1
2
3 *Biol.* **45**
4

5 Sen H T, Lediju Bell M A, Zhang Y, Ding K, Boctor E, Wong J, Iordachita I and Kazanzides P 2017
6 System Integration and in Vivo Testing of a Robot for Ultrasound Guidance and Monitoring
7 during Radiotherapy *IEEE Trans. Biomed. Eng.* **64** 1608–18

8 Seppenwoolde Y, Berbeco R I, Nishioka S, Shirato H and Heijmen B 2007 Accuracy of tumor motion
9 compensation algorithm from a robotic respiratory tracking system: a simulation study. *Med.*
10 *Phys.* **34** 2774–84

11 Seppenwoolde Y, Shirato H, Kitamura K, Shimizu S, Van Herk M, V. Lebesque J and Miyasaka K
12 2002 Precise and Real-Time Measurement of 3D Tumor Motion in Lung due to Breathing and
13 Heartbeat, Measured during Radiotherapy *Int. J. Radiat. Oncol.* **53** 822–34

14 Seppenwoolde Y, Wunderink W, Wunderink-van Veen S R, Storchi P, Méndez Romero A and
15 Heijmen B J M 2011 Treatment precision of image-guided liver SBRT using implanted fiducial
16 markers depends on marker-tumour distance. *Phys. Med. Biol.* **56** 5445–68

17 Serban M, Heath E, Stroian G, Collins D L and Seuntjens J 2008 A deformable phantom for 4D
18 radiotherapy verification: Design and image registration evaluation *Med. Phys.* **35** 1094–102

19 Shah A P, Kupelian P A, Waghorn B J, Willoughby T R, Rineer J M, Mañon R R, Vollenweider M A
20 and Meeks S L 2013 Real-time tumor tracking in the lung using an electromagnetic tracking
21 system *Int. J. Radiat. Oncol. Biol. Phys.* **86** 477–83

22 Shah A P, Kupelian P A, Willoughby T R, Langen K M and Meeks S L 2011 An evaluation of
23 intrafraction motion of the prostate in the prone and supine positions using electromagnetic
24 tracking *Radiother. Oncol.* **99** 37–43

25 Shchory T, Harel T, Lifshitz I, Kornblau G, Neustadter D and Corn B 2009 Accuracy of a Radioactive
26 Tracking System in Canine Prostate *Radiat. Oncol. Biol.* **75** S587

27 Shi X, Diwanji T, Mooney K E, Lin J, Feigenberg S, D’Souza W D and Mistry N N 2014 Evaluation
28 of template matching for tumor motion management with cine-MR images in lung cancer
29 patients *Med. Phys.* **41**

30 Shieh C C, Caillet V, Dunbar M, Keall P J, Booth J T, Hardcastle N, Haddad C, Eade T and Feain I
31 2017 A Bayesian approach for three-dimensional markerless tumor tracking using kV imaging
32 during lung radiotherapy *Phys. Med. Biol.* **62** 3065–80

33 Shiinoki T, Hanazawa H, Yuasa Y, Fujimoto K, Uehara T and Shibuya K 2017 Verification of
34 respiratory-gated radiotherapy with new real-time tumour-tracking radiotherapy system using
35 cine EPID images and a log file *Phys. Med. Biol.* **62** 1585–99

36 Shimizu S, Miyamoto N, Matsuura T, Fujii Y, Umezawa M, Umegaki K, Hiramoto K and Shirato H
37 2014 A proton beam therapy system dedicated to spot-scanning increases accuracy with moving
38 tumors by real-time imaging and gating and reduces equipment size *PLoS One* **9** 3–9

39 Shinohara E T, Kassaei A, Mitra N, Vapiwala N, Plastaras J P, Drebin J, Wan F and Metz J M 2012
40 Feasibility of electromagnetic transponder use to monitor inter- and intrafractional motion in
41 locally advanced pancreatic cancer patients *Int. J. Radiat. Oncol. Biol. Phys.* **83** 566–73

42 Shirato H, Oita M, Fujita K, Watanabe Y and Miyasaka K 2004 Feasibility of synchronization of real-
43 time tumor-tracking radiotherapy and intensity-modulated radiotherapy from viewpoint of
44 excessive dose from fluoroscopy *Int. J. Radiat. Oncol. Biol. Phys.* **60** 335–41

45 Shirato H, Onimaru R, Ishikawa M, Kaneko J I, Takeshima T, Mochizuki K, Shimizu S and Umegaki
46 K 2012 Real-time 4-D radiotherapy for lung cancer *Cancer Sci.* **103** 1–6

47 Shirato H, Shimizu S, Kitamura K and Onimaru R 2007 Organ motion in image-guided radiotherapy:
48 Lessons from real-time tumor-tracking radiotherapy *Int. J. Clin. Oncol.* **12** 8–16

49 Shirato H, Shimizu S, Kunieda T, Kitamura K, Van Herk M, Kagei K, Nishioka T, Hashimoto S,
50 Fujita K, Aoyama H, Tsuchiya K, Kudo K and Miyasaka K 2000 Physical aspects of a real-time

1 tumor-tracking system for gated radiotherapy *Int. J. Radiat. Oncol. Biol. Phys.* **48** 1187–95

2 Shirato H, Shimizu S, Shimizu T, Nishioka T and Miyasaka K 1999 Real-time tumour-tracking

3 radiotherapy *Lancet* **353** 1331–2

4 Von Siebenthal M, Székely G, Gamper U, Boesiger P, Lomax A and Cattin P 2007 4D MR imaging

5 of respiratory organ motion and its variability *Phys. Med. Biol.* **52** 1547–64

6 Sihono D S K, Vogel L, Weiß C, Thölking J, Wenz F, Lohr F, Boda-Heggemann J and Wertz H 2017

7 A 4D ultrasound real-time tracking system for external beam radiotherapy of upper abdominal

8 lesions under breath-hold *Strahlentherapie und Onkol.* **19** 213–20

9 Siochi R A, Kim Y and Bhatia S 2015 Tumor control probability reduction in gated radiotherapy of

10 non-small cell lung cancers: a feasibility study *J. Appl. Clin. Med. Phys.* **16** 4444

11 Skouboe S, Ravkilde T, Bertholet J, Hansen R, Worm E S, Muurholm C G, Weber B, Høyer M and

12 Poulsen P R 2019 OC-0543 First clinical real-time motion-including tumour dose reconstruction

13 during radiotherapy *Radiother. Oncol.* **133** S286

14 Van Sörnsen De Koste J R, Dahele M, Mostafavi H, Sloutsky A, Senan S, Slotman B J and Verbakel

15 W F A R 2015 Markerless tracking of small lung tumors for stereotactic radiotherapy *Med.*

16 *Phys.* **42** 1640–52

17 Steidl P, Richter D, Schuy C, Schubert E, Haberer T, Durante M and Bert C 2012 A breathing thorax

18 phantom with independently programmable 6D tumour motion for dosimetric measurements in

19 radiation therapy *Phys. Med. Biol.* **57** 2235–50

20 Stemkens B, Tijssen R H N, de Senneville B D, Lagendijk J J W and van den Berg C A T 2016

21 Image-driven, model-based 3D abdominal motion estimation for MR-guided radiotherapy *Phys.*

22 *Med. Biol.* **61** 5335–55

23 Stroom J C and Heijmen B J M 2002 Geometrical uncertainties, radiotherapy planning margins, and

24 the ICRU-62 report *Radiother. Oncol.* **64** 75–83

25 Su L, Iordachita I, Zhang Y, Lee J, Ng S K, Jackson J, Hooker T, Wong J, Herman J M, Tutkun Sen

26 H, Kazanzides P, Lediju Bell M A, Yang C and Ding K 2017a Feasibility study of ultrasound

27 imaging for stereotactic body radiation therapy with active breathing coordinator in pancreatic

28 cancer *J. Appl. Clin. Med. Phys.* **18** 84–96

29 Su T-S, Liang P, Liang J, Lu H-Z, Jiang H-Y, Cheng T, Huang Y, Tang Y and Deng X 2017b Long-

30 term Survival Analysis of Stereotactic Ablative Radiotherapy Versus Liver Resection for Small

31 Hepatocellular Carcinoma *Int. J. Radiat. Oncol. Biol. Phys.* **98** 639–46

32 Su Z, Zhang L, Murphy M and Williamson J 2011 Analysis of prostate patient setup and tracking

33 data: Potential intervention strategies *Int. J. Radiat. Oncol. Biol. Phys.* **81** 880–7

34 Tang X, Sharp G C and Jiang S B 2007 Fluoroscopic tracking of multiple implanted fiducial markers

35 using multiple object tracking *Phys. Med. Biol.* **52** 4081–98

36 Tang X, Zagar T M, Bair E, Jones E L, Fried D, Zhang L, Tracton G, Xu Z, Leach T, Chang S and

37 Marks L B 2014 Clinical experience with 3-dimensional surface matching-based deep

38 inspiration breath hold for left-sided breast cancer radiation therapy *Pract. Radiat. Oncol.* **4**

39 e151–8

40 Tetar S, Bruynzeel A, Bakker R, Jeulink M, Slotman B J, Oei S, Haasbeek C, De Jong K, Senan S and

41 Lagerwaard F 2018 Patient-reported Outcome Measurements on the Tolerance of Magnetic

42 Resonance Imaging-guided Radiation Therapy *Cureus* **10**

43 Thomas D, Lamb J, White B, Jani S, Gaudio S, Lee P, Ruan D, McNitt-Gray M and Low D 2014 A

44 novel fast helical 4D-CT acquisition technique to generate low-noise sorting artifact-free images

45 at user-selected breathing phases *Int. J. Radiat. Oncol. Biol. Phys.* **89** 191–8 Online:

46 <http://dx.doi.org/10.1016/j.ijrobp.2014.01.016>

47 Tijssen R H N, Philippens M E P, Paulson E S, Glitzner M, Chugh B, Wetscherek A, Dubec M, Wang

1
2
3 J and van der Heide U A 2019 MRI commissioning of 1.5T MR-linac systems – a multi-
4 institutional study *Radiother. Oncol.* **132** 114–20
5
6 Toftegaard J, Hansen R, Ravkilde T, Macek K and Poulsen P R 2017 An experimentally validated
7 couch and MLC tracking simulator used to investigate hybrid couch-MLC tracking *Med. Phys.*
8 **44** 798–809
9
10 Tran E H, Eiben B, Wetscherek A, Collins D J, Oelfke U, Meedt G, Hawkes D J and McClelland J R
11 2018 OC-0411: Investigation of MRI-derived surrogate signals for modelling respiratory motion
12 on an MRI-Linac *Radiother. Oncol.* **127** S211–2
13
14 Trmková P, Knäusl B, Actis O, Bert C, Biegum A K, Boehlen T T, Furtado H, McClelland J, Mori S,
15 Rinaldi I, Rucinski A and Knopf A C 2018 Clinical implementations of 4D pencil beam scanned
16 particle therapy: Report on the 4D treatment planning workshop 2016 and 2017 *Phys. Medica* **54**
17 121–30
18
19 Tryggestad E, Flammang A, Hales R, Herman J, Lee J, McNutt T, Roland T, Shea S M and Wong J
20 2013 4D tumor centroid tracking using orthogonal 2D dynamic MRI: Implications for
21 radiotherapy planning *Med. Phys.* **40** 091712
22
23 Tynan M, Stevens R, Parsons D D and Robar J L 2016 Continuous monitoring of prostate position
24 using stereoscopic and monoscopic kV image guidance *Med. Phys. Med. Phys.* **43** 2558–68
25
26 Ueki N, Matsuo Y, Nakamura M, Mukumoto N, Iizuka Y, Miyabe Y, Sawada A, Mizowaki T,
27 Kokubo M and Hiraoka M 2014 Intra- and interfractional variations in geometric arrangement
28 between lung tumours and implanted markers *Radiother. Oncol.* **110** 523–8
29
30 Umezawa M, Ebina F, Fujii Y, Matsuda K, Hiramoto K, Umegaki K and Shirato H 2015
31 Development of compact proton beam therapy system for moving organs *Hitachi Rev.* **64** 506–
32 13
33
34 Vandemeulebroucke J, Kybic J, Clarysse P and Sarrut D 2009 Respiratory Motion Estimation from
35 Cone-Beam Projections Using a Prior Model 365–72
36
37 Vanhanen A and Kapanen M 2016 The effect of rectal retractor on intrafraction motion of the prostate
38 *Biomed. Phys. Eng. Express* **2** 035021
39
40 Vanhanen A, Syrén H and Kapanen M 2018 Localization accuracy of two electromagnetic tracking
41 systems in prostate cancer radiotherapy: A comparison with fiducial marker based kilovoltage
42 imaging *Phys. Medica* **56** 10–8
43
44 Verellen D, Tournel K, Van de Steene J, Linthout N, Wauters T, Vinh-Hung V and Storme G 2006
45 Breathing-synchronized irradiation using stereoscopic kV-imaging to limit influence of interplay
46 between leaf motion and organ motion in 3D-CRT and IMRT: Dosimetric verification and first
47 clinical experience *Int. J. Radiat. Oncol.* **66** S108–19
48
49 Vinogradskiy Y, Goodman K A, Schefter T, Miften M and Jones B L 2018 The clinical and
50 dosimetric impact of real-time target tracking in pancreatic SBRT *Int. J. Radiat. Oncol.* **103**
51 268–75
52
53 Vogel L, Sihono D S K, Weiss C, Lohr F, Stieler F, Wertz H, von Swietochowski S, Simeonova-
54 Chergou A, Wenz F, Blessing M and Boda-Heggemann J 2018 Intra-breath-hold residual motion
55 of image-guided DIBH liver-SBRT: An estimation by ultrasound-based monitoring correlated
56 with diaphragm position in CBCT *Radiother. Oncol.* **129** 441–8
57
58 Wan H, Bertholet J, Ge J, Poulsen P and Parikh P 2016 Automated patient setup and gating using
59 cone beam computed tomography projections *Phys. Med. Biol.* **61** 2552–61
60
61 Wan H, Ge J and Parikh P 2014 Using dynamic programming to improve fiducial marker localization.
62 *Phys. Med. Biol.* **59** 1935–46
63
64 Willoughby T, Lehmann J, Bencomo J A, Jani S K, Santanam L, Sethi A, Solberg T D, Tomé W A
65 and Waldron T J 2012 Quality assurance for nonradiographic radiotherapy localization and

1 positioning systems: Report of Task Group 147 *Med. Phys.* **39** 1728–47

2 Willoughby T R, Forbes A R, Buchholz D, Langen K M, Wagner T H, Zeidan O A, Kupelian P A and

3 Meeks S L 2006a Evaluation of an infrared camera and X-ray system using implanted fiducials

4 in patients with lung tumors for gated radiation therapy *Int. J. Radiat. Oncol. Biol. Phys.* **66**

5 568–75

6 Willoughby T R, Kupelian P A, Pouliot J, Shinohara K, Aubin M, Roach M, Skrumeda L L, Balter J

7 M, Litzenberg D W, Hadley S W, Wei J T and Sandler H M 2006b Target localization and real-

8 time tracking using the Calypso 4D localization system in patients with localized prostate cancer

9 *Int. J. Radiat. Oncol. Biol. Phys.* **65** 528–34

10 Wolf R and Bortfeld T 2012 An analytical solution to proton Bragg peak deflection in a magnetic

11 field *Phys. Med. Biol.* **57**

12 Wolfelschneider J, Seregni M, Fassi A, Ziegler M, Baroni G, Fietkau R, Riboldi M and Bert C 2017

13 Examination of a deformable motion model for respiratory movements and 4D dose calculations

14 using different driving surrogates *Med. Phys.* **44** 2066–76

15 Wolthaus J W H, Sonke J J, van Herk M, Belderbos J S A, Rossi M M G, Lebesque J V. and Damen

16 E M F 2008 Comparison of Different Strategies to Use Four-Dimensional Computed

17 Tomography in Treatment Planning for Lung Cancer Patients *Int. J. Radiat. Oncol. Biol. Phys.*

18 **70** 1229–38

19 Wong J W, Sharpe M B, Jaffray D A, Kini V R, Robertson J M, Stromberg J S and Martinez A A

20 1999 The use of active breathing control (ABC) to reduce margin for breathing motion *Int. J.*

21 *Radiat. Oncol. Biol. Phys.* **44** 911–9

22 Worm E S, Bertholet J, Høyer M, Fledelius W, Hansen A T, Larsen L P, Nielsen J E and Poulsen P R

23 2016 Fiducial marker guided stereotactic liver radiotherapy : Is a time delay between marker

24 implantation and planning CT needed ? *Radiother. Oncol.* **121** 75–8

25 Worm E S, Høyer M, Fledelius W, Nielsen J E, Larsen L P and Poulsen P R 2012 On-line use of

26 three-dimensional marker trajectory estimation from cone-beam computed tomography

27 projections for precise setup in radiotherapy for targets with respiratory motion. *Int. J. Radiat.*

28 *Oncol. Biol. Phys.* **83** e145-51

29 Worm E S, Høyer M, Fledelius W and Poulsen P R 2013 Three-dimensional, time-resolved,

30 intrafraction motion monitoring throughout stereotactic liver radiation therapy on a conventional

31 linear accelerator. *Int. J. Radiat. Oncol. Biol. Phys.* **86** 190–7

32 Worm E S, Høyer M, Hansen R, Larsen L P, Weber B, Grau C and Poulsen P R 2018 A Prospective

33 Cohort Study of Gated Stereotactic Liver Radiation Therapy Using Continuous Internal

34 Electromagnetic Motion Monitoring *Int. J. Radiat. Oncol. Biol. Phys.* **101** 366–75

35 Xu Q, Hanna G, Grimm J, Kubicek G, Pahlajani N, Asbell S, Fan J, Chen Y and LaCouture T 2014

36 Quantifying Rigid and Nonrigid Motion of Liver Tumors During Stereotactic Body Radiation

37 Therapy *Int. J. Radiat. Oncol. Biol. Phys.* **90** 94–101

38 Yamada T, Miyamoto N, Matsuura T, Takao S, Fujii Y, Matsuzaki Y, Koyano H, Umezawa M,

39 Nihongi H, Shimizu S, Shirato H and Umegaki K 2016 Optimization and evaluation of multiple

40 gating beam delivery in a synchrotron-based proton beam scanning system using a real-time

41 imaging technique *Phys. Medica* **32** 932–7

42 Yip E, Yun J, Gabos Z, Baker S, Yee D, Wachowicz K, Rathee S and Fallone B G 2018 Evaluating

43 performance of a user-trained MR lung tumor autocontouring algorithm in the context of intra-

44 and interobserver variations *Med. Phys.* **45** 307–13

45 Yun J, Yip E, Gabos Z, Wachowicz K, Rathee S and Fallone B G 2015 Neural-network based

46 autocontouring algorithm for intrafractional lung-tumor tracking using Linac-MR *Med. Phys.* **42**

47 2296–310

48 Zagar T M, Kaidar-Person O, Tang X, Jones E E, Matney J, Das S K, Green R L, Sheikh A, Khandani

1
2
3 A H, McCartney W H, Oldan J D, Wong T Z and Marks L B 2017 Utility of Deep Inspiration
4 Breath Hold for Left-Sided Breast Radiation Therapy in Preventing Early Cardiac Perfusion
5 Defects: A Prospective Study *Int. J. Radiat. Oncol. Biol. Phys.* **97** 903–9
6
7 Zhang P, Happersett L, Ravindranath B, Zelefsky M, Mageras G and Hunt M 2016 Optimizing
8 fiducial visibility on periodically acquired megavoltage and kilovoltage image pairs during
9 prostate volumetric modulated arc therapy *Med. Phys.* **43** 2024–9
10
11 Zhang P, Hunt M, Telles A B, Pham H, Lovelock M, Yorke E, Li G, Happersett L, Rimner A and
12 Mageras G 2018 Design and validation of a MV/kV imaging based markerless tracking system
13 for assessing real time lung tumor motion *Med. Phys.* **45** 5555–63 Online:
14 <http://doi.wiley.com/10.1002/mp.13259>
15
16 Zhang X, Homma N, Ichiji K, Abe M, Sugita N, Takai Y, Narita Y and Yoshizawa M 2014a A
17 kernel-based method for markerless tumor tracking in kV fluoroscopic images *Phys. Med. Biol.*
18 **59** 4897–911
19
20 Zhang Y, Knopf A C, Weber D C and Lomax A J 2015 Improving 4D plan quality for PBS-based
21 liver tumour treatments by combining online image guided beam gating with rescanning *Phys.*
22 *Med. Biol.* **60** 8141–59
23
24 Zhang Y, Knopf A, Tanner C, Boye D and Lomax A J 2013 Deformable motion reconstruction for
25 scanned proton beam therapy using on-line x-ray imaging *Phys. Med. Biol.* **58**
26
27 Zhang Y, Knopf A, Tanner C and Lomax A J 2014b Online image guided tumour tracking with
28 scanned proton beams: A comprehensive simulation study *Phys. Med. Biol.* **59** 7793–817
29
30 Zhu M, Bharat S, Michalski J M, Gay H A, Hou W H and Parikh P J 2013 Adaptive radiation therapy
31 for postprostatectomy patients using real-time electromagnetic target motion tracking during
32 external beam radiation therapy *Int. J. Radiat. Oncol. Biol. Phys.* **85** 1038–44
33
34 Zhu X, Bourland J D, Yuan Y, Zhuang T, O'Daniel J, Thongphiew D, Wu Q J, Das S K, Yoo S and
35 Yin F F 2009 Tradeoffs of integrating real-time tracking into IGRT for prostate cancer treatment
36 *Phys. Med. Biol.* **54** N393–401
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60